

## The Historical/Evolutionary Cause and Possible Treatment of Pandemic Covid-19 (SARS-CoV-2, 2019-Coronavirus)

*(World-War III: The Blackout of The Modern World by Neglected Small Infectious Agent)*

Sorush Niknamian<sup>1\*</sup>, Somayeh Zaminpira<sup>2</sup>

<sup>1</sup>American Military University and Liberty University, Military Medicine Department, USA

<sup>2</sup>American Beirut University, Phycology and Psychiatry Department, Beirut, Lebanon

**\*Corresponding author:** Sorush Niknamian, American Military University and Liberty University, Military Medicine Department, USA. Email: So.niknamian@gmail.com; ss.violet61@gmail.com

**Citation:** Niknamian S and Zaminpira S (2020) The Historical/Evolutionary Cause and Possible Treatment of Pandemic Covid-19 (SARS-CoV-2, 2019-Coronavirus). Annal Cas Rep Rev: ACRR-110.

**Received Date:** 18 April 2020; **Accepted Date:** 23 April 2020; **Published Date:** 30 April 2020

### Abstract

**Background:** A virus is a small infectious agent that replicates only inside the living cells of an organism. Viruses can infect all types of life forms, from animals and plants to microorganisms, including bacteria and archaea. In evolution, viruses are an important means of horizontal gene transfer, which increases genetic diversity in a way analogous to sexual reproduction. Influenza (Including (COVID-19), is an infectious disease caused by an influenza virus. Some viruses especially smallpox, throughout history, has killed between 300-500 million people in its 12,000-year existence. As modern humans increased in numbers, new infectious diseases emerged, including SARS-CoV-2. We have two groups of virus, RNA and DNA viruses. The most brutal viruses are RNA ones like COVID-19 (Sars-CoV-2 [1].

**Introduction:** Coronaviruses are a group of viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that are typically mild, such as some cases of the common cold (among other possible causes, predominantly rhinoviruses), though rarer forms can be lethal, such as SARS, MERS, and COVID-19. Symptoms vary in other species: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. Coronaviruses constitute the subfamily Orthocoronavirinae, the genome size, coronaviruses ranges from approximately 27 to 34 kilobases, the largest among known RNA viruses.

**Discussions and Results:** We have researched from the first virus in the planet to the last mutated version which is SARS-COV-2. We have collected many informative data in tables and figures to reach the main cause of 2019-Coronavirus and calculated the probability and estimated deaths in the current time. We have discussed about the possible treatment and prevention of the virus and did algebraic calculations on the epidemiology, the size and even the future of this pandemic. The only era which any virus had not been epidemic, were through world war 2, were the German scientists had found the way to fight any viral infections which is very important and can help scientists to reach the main treatment of the new 2019-Coronavirus. We have sorted the deadly and non-deadly coronaviruses and explained how this epidemic had begun through Evolutionary Medicine (EM). The result of the article is that 16% of the whole population in the world has been contaminated which is 1248000000 of 7.8 billion people world-wide. SARS-CoV-2 is an RNA Virus. its nucleic acid is single-stranded RNA (ssRNA). The polarity of this virus is positive-sense ((+) ssRNA). Positive-sense viral RNA is similar to mRNA and thus can be immediately translated by the host cell. Recombination in RNA viruses appears to be an adaptation for coping with genome damage. Recombination can occur infrequently between animal viruses of the same species but of divergent lineages. The resulting recombinant viruses may sometimes cause an outbreak of infection in humans. RNA viruses have very high mutation rates This is one reason why it is difficult to make effective vaccines to prevent diseases caused by RNA viruses. The resulting recombinant viruses causes an outbreak of infection in humans.

**Conclusion:** In conclusion, the mutation of the SARS-CoV and influenza viruses through Drift and Reassortment is the main cause of SARS-CoV-2 through natural selection, Lamarckian Evolution and coevolution which caused this RNA virus so powerful, unpredicted and different in the genome size and nations worldwide. The first Pandemic of Influenza was first detected in 1732 and this virus evolved through natural selection till 2019 which caused the worldwide pandemic of SARS-CoV-2. Based on many studies, inhalation of Ozone plus Sulfur Dioxide, increasing the amounts of L-Glutathione (Which is low in children and older adults and this is the main reason why older adults and children die from this disease.) plus Viral Phage Therapy (VPT) which we discussed fully in this article can be the possible prime treatment of SARS-CoV-2 infection. The seasonal temperature cannot be useful in controlling/reducing the pandemic of this virus since the natural selection, Lamarckian Evolution and high mutation of the virus helps its survival. No antiviral drugs will be useful against SARS-CoV-2 because of high rate of mutation and primarily adaptation of the virus to the drugs and even the environmental Temperature.

**Keywords:** COVID-19 (SARS-CoV-2), Positive-Sense ((+) ssRNA), Viral Phage Therapy, Sulfur Dioxide, Ozone, Influenza, Natural Selection, Lamarckian Evolution, Fibonacci Series, L-Glutathione, Drift, Reassortment, Pandemic.

## Introduction

### Brief History of Viruses


#### Prehistory

The world, new infectious diseases emerged, including those caused by viruses. [1] Earlier, humans lived in small, isolated communities, and most epidemic diseases did not exist. [2][3] Smallpox, which is the most lethal and devastating viral infection in history, first emerged among agricultural communities in India about 11,000 years ago. [4] The virus, which only infected humans, probably descended from the poxviruses of rodents. [5] Humans probably came into contact with these rodents, and some people became infected by the viruses they carried. When viruses cross this so-called "species barrier", their effects can be severe, [6] and humans may have had little natural resistance. Contemporary humans lived in small communities, and those who succumbed to infection either died or developed immunity. This acquired immunity is only passed down to offspring temporarily, by antibodies in breast milk and other antibodies that cross the placenta from the mother's blood to the unborn child's. Therefore, sporadic outbreaks probably occurred in each generation. In about 9000 BC, when many people began to settle on the fertile flood plains of the River Nile, the population became dense enough for the virus to maintain a constant presence because of the high concentration of susceptible people.[7] Other epidemics of viral diseases that depend on large concentrations of people, such as mumps, rubella and polio, also first occurred at this time.[8] The Neolithic age, which began in the Middle East in about 9500 BC, was a time when humans became farmers.[9] This agricultural revolution embraced the development of monoculture and presented an opportunity for the rapid spread of several species of plant viruses.[10] The divergence and spread of sobemoviruses – southern bean mosaic virus – date from this time. [11] The spread of the potyviruses of potatoes, and other fruits and vegetables, began about 6,600 years ago. [10] About 10,000 years ago the humans who inhabited the lands around the Mediterranean basin began to domesticate wild animals. Pigs, cattle, goats, sheep, horses, camels, cats and dogs were all kept and bred in captivity. [12] These animals would have brought their viruses with them. [13] The transmission of viruses from animals to humans can occur, but such zoonotic infections are rare and subsequent human-to-human transmission of animal viruses is even rarer, although there are notable exceptions such as influenza. Most viruses are species-specific and would have posed no threat to humans. [14] The rare epidemics of viral diseases originating in animals would have been short-lived because the viruses were not fully adapted to humans [15] and the human populations were too small to maintain the chains of infection [16].

Other, more ancient, viruses have been less of a threat. Herpes viruses first infected the ancestors of modern humans over 80 million years ago [17]. Humans have developed a tolerance to these viruses, and most are infected with at least one species. [18] Records of these milder virus infections are rare, but it is likely that early hominids suffered from colds, influenza and diarrhoea caused by viruses just as humans do today. More recently evolved viruses cause epidemics and pandemics. [17] The influenza virus is one that seems to have crossed the species barrier from ducks and water fowl to pigs and from there to humans. It is possible that a fatal plague in the Middle East at the time of the late 18th Dynasty was associated with this transmission at Amarna. [19-20].

#### Influenza

Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus.[21] Symptoms can be mild to severe.[25] The most common symptoms include: high fever, runny nose, sore throat, muscle and joint pain, headache, coughing, and feeling tired just like Sars-CoV-2.[21] These symptoms typically begin two days after exposure to the virus and most last less than a week.[21] The cough, however, may last for more than two weeks.[21] In children, there may be diarrhea and vomiting, but these are not common in adults.[26] Diarrhea and vomiting occur more commonly in gastroenteritis, which is an unrelated disease and sometimes inaccurately referred to as stomach flu or the 24-hour flu..[26] Complications of influenza may include viral pneumonia, secondary bacterial pneumonia, sinus infections, and worsening of previous health problems such as asthma or heart failure.[22][25] Three of the four types of influenza viruses affect humans: Type A, Type B, and Type C.[22][27] Type D has not been known to infect humans, but is believed to have the potential to do so.[27][28] Usually, the virus is spread through the air from coughs or sneezes.[21] This is believed to occur mostly over relatively short distances.[29] It can also be spread by touching surfaces contaminated by the virus and then touching the eyes, nose, or mouth.[25][29][30] A person may be infectious to others both before and during the time they are showing symptoms.[25] The infection may be confirmed by testing the throat, sputum, or nose for the virus.[22] A number of rapid tests are available; however, people may still have the infection even if the results are negative.[22] A type of polymerase chain reaction that detects the virus's RNA is more accurate [22].




**Picture 1:** Influenza virus, magnified approximately 100,000 times, Specialty: Infectious disease, Symptoms: Fever, runny nose, sore throat, muscle and joint pain, headache, coughing, feeling tired, Usual onset: One to four days after exposure, Duration: 1 week, Causes: Influenza viruses. Prevention: Hand washing, influenza vaccine, surgical masks, Frequency: 3-5 million severe cases per year. Deaths: Up to 650,000 respiratory deaths per year. [1-3]

Symptom:	<a href="#">sensitivity</a>	<a href="#">specificity</a>
Fever	68-86%	25-73%
Cough	84-98%	7-29%
Nasal congestion	68-91%	19-41%

- All three findings, especially fever, were less sensitive in people over 60 years of age.


**Table 1:** Most sensitive symptoms for diagnosing influenza [1-3]



**Picture 2:** Symptoms of influenza, with fever and cough the most common symptoms [20-22].



**Picture 3:** 29 yr. old with H1N1 with high inflammation in the lungs and respiratory systems.



**Picture 4:** Seasonal risk areas for influenza: November–April (blue), April–November (red), and year-round (yellow). [21]

**List of epidemics of Plagues**

Death toll (estimate)	Location	Date	Event	Disease
75,000–100,000	<u>Greece</u>	429–426 BC	<u>Plague of Athens</u>	Unknown, possibly <u>typhus</u> , <u>typhoid fever</u> or <u>viral hemorrhagic fever</u>
5–10 million	<u>Roman Empire</u>	165–180 (possibly up to 190)	<u>Antonine Plague</u>	Unknown, possibly <u>smallpox</u>
	<u>Europe</u>	250–266	<u>Plague of Cyprian</u>	Unknown, possibly <u>smallpox</u>
25–50 million; 40% of population	<u>Europe, Egypt and West Asia</u>	541–542	<u>Plague of Justinian</u>	<u>Plague</u>
	<u>Rome</u>	590	<u>Roman Plague of 590</u>	<u>Plague</u>
> 100,000	<u>Ctesiphon, Persia</u>	627–628	<u>Plague of Sheroe</u>	<u>Plague</u>

Death toll (estimate)	Location	Date	Event	Disease
	<u>British Isles</u>	664–689	<u>Plague of 664</u>	<u>Plague</u>
	<u>Japan</u>	735–737	<u>735–737 Japanese smallpox epidemic</u>	<u>Smallpox</u>
	<u>Byzantine Empire, West Asia, Africa</u>	746–747	<u>Plague of 746–747</u>	<u>Plague</u>
20–200 million; 20–60% of European population	<u>Europe, Asia and North Africa</u>	1331–1353	<u>Black Death</u>	<u>Plague</u> Y. pestis
> 10,000	<u>England and later continental Europe</u>	1485–1551	<u>Sweating sickness (multiple outbreaks)</u>	Unknown, possibly an unknown species of <u>hantavirus</u>

**Table 2:** 15th Century and earlier.

Death toll (estimate)	Location	Date	Event	Disease	Ref.
5–15 million (80% of population)	<u>Mexico</u>	1545–1548	<u>Cocoliztli Epidemic of 1545–1548</u>	Possibly <u>Salmonella enterica</u>	[50][51][52][53]
2–2.5 million (50% of population)	<u>Mexico</u>	1576–1580	<u>Cocoliztli epidemic of 1576</u>	Possibly <u>Salmonella enterica</u>	[50][51][52][53]
280,000	<u>Italy</u>	1629–1631	<u>Italian plague of 1629–1631</u>	<u>Plague</u>	[60]
100,000 <sup>[33]</sup>	<u>England</u>	1665–1666	<u>Great Plague of London</u>	<u>Plague</u>	[67]
76,000	<u>Austria</u>	1679	<u>Great Plague of Vienna</u>	<u>Plague</u>	
40,000	<u>France</u>	1668		<u>Plague</u>	[68]
30–90% of population	<u>Southern New England, especially the Wampanoag people</u>	1616–1619	<u>1616 New England epidemic</u>	Unknown cause. Latest research suggests epidemic(s) of <u>leptospirosis</u> with <u>Weil syndrome</u> . Classic explanations include <u>yellow fever</u> , <u>bubonic plague</u> , <u>influenza</u> , <u>smallpox</u> , <u>chickenpox</u> , <u>typhus</u> , and <u>syndemic infection of hepatitis B and hepatitis D</u> .	[58][59]
24,148 <sup>[32]</sup>	<u>Netherlands</u>	1663–1664		<u>Plague</u>	
> 20,100 in London	<u>London</u>	1563–1564	<u>1563 London plague</u>	<u>Plague</u>	
> 19,900 in London and outer parishes	<u>London</u>	1592–1593	<u>1592–93 London plague</u>	<u>Plague</u>	
	<u>Seneca nation</u>	1592–1596		<u>Measles</u>	[54]
	<u>Spain</u>	1596–1602		<u>Plague</u>	[55]
	<u>South America</u>	1600–1650		<u>Malaria</u>	[56]
	<u>England</u>	1603		<u>Plague</u>	[57]
	<u>Egypt</u>	1609		<u>Plague</u>	
	<u>Wyandot people</u>	1634		<u>Smallpox</u>	[61]

Death toll (estimate)	Location	Date	Event	Disease	Ref.
	<u>Thirteen Colonies</u>	1633	<u>Massachusetts smallpox epidemic</u>	<u>Smallpox</u>	
	<u>England</u>	1636		<u>Plague</u>	[62]
	<u>China</u>	1641–1644		<u>Plague</u>	[63]
	<u>Spain</u>	1647–1652	<u>Great Plague of Seville</u>	<u>Plague</u>	
	<u>Central America</u>	1648		<u>Yellow fever</u>	[64]
	<u>Italy</u>	1656	<u>Naples Plague</u>	<u>Plague</u>	[65]
	<u>Thirteen Colonies</u>	1657		<u>Measles</u>	[66]
	<u>Spain</u>	1676–1685		<u>Plague</u>	[67]
	<u>Thirteen Colonies</u>	1687		<u>Measles</u>	[68]
	<u>Thirteen Colonies</u>	1690		<u>Yellow fever</u>	

**Table 3:** 16–17th Centuries.

	<u>Canada, New France</u>	1702–1703		<u>Smallpox</u>	[69]
> 18,000 (36% of population)	<u>Iceland</u>	1707–1709	<u>Great Smallpox Epidemic</u>	<u>Smallpox</u>	
	<u>Denmark, Sweden</u>	1710–1712	<u>Great Northern War plague outbreak</u>	<u>Plague</u>	
	<u>Thirteen Colonies</u>	1713–1715		<u>Measles</u>	[70]
	<u>Canada, New France</u>	1714–1715		<u>Measles</u>	[71]
	<u>France</u>	1720–1722	<u>Great Plague of Marseille</u>	<u>Plague</u>	[72]
	<u>Thirteen Colonies</u>	1721–1722		<u>Smallpox</u>	[73]
	<u>Thirteen Colonies</u>	1729		<u>Measles</u>	[74]
	<u>Spain</u>	1730		<u>Yellow fever</u>	
	<u>Thirteen Colonies</u>	1732–1733		<u>Influenza</u>	[75]
	<u>Canada, New France</u>	1733		<u>Smallpox</u>	[76]
> 50,000	<u>Balkans</u>	1738	<u>Great Plague of 1738</u>	<u>Plague</u>	
	<u>Thirteen Colonies</u>	1738		<u>Smallpox</u>	[77]
	<u>Thirteen Colonies</u>	1739–1740		<u>Measles</u>	
	<u>Italy</u>	1743		<u>Plague</u>	[78]
	<u>Thirteen Colonies</u>	1747		<u>Measles</u>	
	<u>North America</u>	1755–1756		<u>Smallpox</u>	
	<u>North America</u>	1759		<u>Measles</u>	[79]
	<u>North America, West Indies</u>	1761		<u>Influenza</u>	
	<u>North America, present-day Pittsburgh area.</u>	1763		<u>Smallpox</u>	[80]
> 50,000	<u>Russia</u>	1770–1772	<u>Russian plague of 1770–1772</u>	<u>Plague</u>	
	<u>Pacific Northwest natives</u>	1770s		<u>Smallpox</u>	[81]
	<u>North America</u>	1772		<u>Measles</u>	
> 2,000,000	<u>Persia</u>	1772	<u>1772 Persia plague</u>	<u>Plague</u>	[81]

	<u>England</u>	1775–1776		<u>Influenza</u>	[82]
	<u>Spain</u>	1778		<u>Dengue fever</u>	[83]
	<u>Plains Indians</u>	1780–1782	<u>North American smallpox epidemic</u>	<u>Smallpox</u>	[84]
	<u>Pueblo Indians</u>	1788		<u>Smallpox</u>	[85]
	<u>United States</u>	1788		<u>Measles</u>	
	<u>New South Wales, Australia</u>	1789–1790		<u>Smallpox</u>	[86]
	<u>United States</u>	1793		<u>Influenza and Epidemic Typhus</u>	
	<u>United States</u>	1793–1798	<u>Yellow Fever Epidemic of 1793, resurgences</u>	<u>Yellow fever</u>	[87]

**Table 4:** 18th Century.

<b>Death toll (estimate)</b>	<b>Location</b>	<b>Date</b>	<b>Event</b>	<b>Disease</b>	<b>Ref.</b>
1,000,000	<u>Russia</u>	1852–1860	<u>Third cholera pandemic</u>	<u>Cholera</u>	[88]
1,000,000	Worldwide	1889–1890	<u>1889–1890 flu pandemic</u>	<u>Influenza</u>	[83]
> 100,000	<u>Asia, Europe</u>	1816–1826	<u>First cholera pandemic</u>	<u>Cholera</u>	[89]
> 100,000	<u>Asia, Europe, North America</u>	1829–1851	<u>Second cholera pandemic</u>	<u>Cholera</u>	[89]
40,000	<u>Fiji</u>	1875	<u>1875 Fiji Measles outbreak</u>	<u>Measles</u>	[81]
> 20,000	<u>Canada</u>	1847–1848	<u>Typhus epidemic of 1847</u>	<u>Epidemic typhus</u>	[69]
> 9,000	<u>India, Germany</u>	1881–1896	<u>Fifth cholera pandemic</u>	<u>Cholera</u>	[89]
4,737	<u>Copenhagen, Denmark</u>	1853	<u>Cholera epidemic of Copenhagen 1853</u>	<u>Cholera</u>	[73]
3,164	<u>Montreal</u>	1885		<u>Smallpox</u>	timeline
> 3,000	<u>Central Coast, British Columbia</u>	1862–1863		<u>Smallpox</u>	[78]
616	<u>England</u>	1854	<u>Broad Street cholera outbreak</u>	<u>Cholera</u>	[74]
	<u>Spain</u>	1800–1803		<u>Yellow fever</u>	[86]
	<u>Ottoman Empire, Egypt</u>	1801		<u>Bubonic plague</u>	[87]
	<u>United States</u>	1803		<u>Yellow fever</u>	
	<u>Egypt</u>	1812		<u>Plague</u>	
	<u>Ottoman Empire</u>	1812		<u>Plague</u>	[88]
	<u>Malta</u>	1813		<u>Plague</u>	
	<u>Romania</u>	1813	<u>Caragea's plague</u>	<u>Plague</u>	
	<u>Ireland</u>	1816–1819		<u>Typhus</u>	
	<u>United States</u>	1820–1823		<u>Yellow fever</u>	
	<u>Spain</u>	1821		<u>Yellow fever</u>	[90]
	<u>New South Wales, Australia</u>	1828		<u>Smallpox</u>	[91]
	<u>Netherlands</u>	1829	<u>Groningen epidemic</u>	<u>Malaria</u>	
	<u>South Australia</u>	1829		<u>Smallpox</u>	[92]

Death toll (estimate)	Location	Date	Event	Disease	Ref.
	<u>Iran</u>	1829–1835		<u>Bubonic plague</u>	[93]
	<u>Egypt</u>	1831		<u>Cholera</u>	[94][95]
	<u>Plains Indians</u>	1831–1834		<u>Smallpox</u>	
	<u>England, France</u>	1832		<u>Cholera</u>	
	<u>North America</u>	1832		<u>Cholera</u>	[96]
	<u>United States</u>	1833		<u>Cholera</u>	
	<u>United States</u>	1834		<u>Cholera</u>	
	<u>Egypt</u>	1834–1836		<u>Bubonic plague</u>	[96][97]
	<u>United States</u>	1837		<u>Typhus</u>	
	<u>Great Plains</u>	1837–1838	<u>1837–38 smallpox epidemic</u>	<u>Smallpox</u>	[98]
	<u>Dalmatia</u>	1840		<u>Plague</u>	
	<u>South Africa</u>	1840		<u>Smallpox</u>	
	<u>United States</u>	1841		<u>Yellow fever</u>	
	<u>United States</u>	1847		<u>Yellow fever</u>	
	<u>Worldwide</u>	1847–1848		<u>Influenza</u>	[99]
	<u>Egypt</u>	1848		<u>Cholera</u>	[96][97]
	<u>North America</u>	1848–1849		<u>Cholera</u>	
	<u>United States</u>	1850		<u>Yellow fever</u>	
	<u>North America</u>	1850–1851		<u>Influenza</u>	
	<u>United States</u>	1851		<u>Cholera</u>	[100]
	<u>United States</u>	1852		<u>Yellow fever</u>	
	<u>Ottoman Empire</u>	1853		<u>Plague</u>	[101]
	<u>United States</u>	1855		<u>Yellow fever</u>	
	<u>Worldwide</u>	1855–1960	<u>Third plague pandemic</u>	<u>Bubonic plague</u>	[102]
	<u>Portugal</u>	1857		<u>Yellow fever</u>	
	<u>Victoria, Australia</u>	1857		<u>Smallpox</u>	[103]
	<u>Europe, North America, South America</u>	1857–1859		<u>Influenza</u>	[104]
	<u>Middle East</u>	1863–1879	<u>Fourth cholera pandemic</u>	<u>Cholera</u>	[112]
	<u>Egypt</u>	1865		<u>Cholera</u>	[96][97]
	<u>Russia, Germany</u>	1866–1867		<u>Cholera</u>	
	<u>Australia</u>	1867		<u>Measles</u>	
	<u>Iraq</u>	1867		<u>Plague</u>	[105]
	<u>Argentina</u>	1852–1871		<u>Yellow fever</u>	[106]
	<u>Germany</u>	1870–1871		<u>Smallpox</u>	
	<u>Russian Empire</u>	1877		<u>Plague</u>	[108]
	<u>Egypt</u>	1881		<u>Cholera</u>	[96][97]
	<u>West Africa</u>	1900		<u>Yellow fever</u>	

**Table 5:** 19th Century.



Death toll (estimate)	Location	Date	Event	Disease	Ref.
	<u>Congo Basin</u>	1896–1906		<u>Trypanosomiasis</u>	[109]
> 800,000	<u>Europe, Asia, Africa</u>	1899–1923	<u>Sixth cholera pandemic</u>	<u>Cholera</u>	[85]
113	<u>San Francisco</u>	1900–1904		<u>Bubonic plague</u>	[110]
	<u>Uganda</u>	1900–1920		<u>Trypanosomiasis</u>	[111]
	<u>Egypt</u>	1902		<u>Cholera</u>	96[197]
22	<u>India</u>	1903		<u>Bubonic Plague</u>	[112]
4	<u>Fremantle</u>	1903		<u>Bubonic plague</u>	[113]
40,000	<u>China</u>	1910–1912	<u>1910 China plague</u>	<u>Bubonic plague</u>	[114]
1.5 million	worldwide	1915–1926	<u>1915 Encephalitis lethargica pandemic</u>	<u>Encephalitis lethargica</u>	[115]
up to 100,000,000	worldwide	1918–1920	<u>Spanish flu</u>	<u>Influenza Spanish Flu Virus</u>	[116]
	<u>Russia</u>	1918–1922		<u>Typhus</u>	
30	<u>Los Angeles</u>	1924	<u>1924 Los Angeles pneumonic plague outbreak</u>	<u>Pneumonic plague</u>	
43	<u>Croydon, UK</u>	1937	<u>Croydon epidemic of typhoid fever</u>	<u>Typhoid fever</u>	[117]
	<u>Egypt</u>	1942–1944		<u>Malaria</u>	96[197]
	<u>China</u>	1946		<u>Bubonic plague</u>	
	<u>Egypt</u>	1946		<u>Relapsing fever</u>	96[197]
	<u>Egypt</u>	1947		<u>Cholera</u>	96[197]
2,000,000	worldwide	1957–1958	<u>Asian flu</u>	<u>Influenza</u>	[118]
	worldwide	1961–1975	<u>Seventh cholera pandemic</u>	<u>Cholera</u>	[110]
4	<u>Sweden</u>	1963		<u>Smallpox</u>	[119][120]
1,000,000	worldwide	1968–1969	<u>Hong Kong flu</u>	<u>Influenza</u>	[118]
5	<u>Netherlands</u>	1971		<u>Poliomyelitis</u>	[121]
35	<u>Yugoslavia</u>	1972	<u>1972 outbreak of smallpox in Yugoslavia</u>	<u>Smallpox</u>	
	<u>United States</u>	1972–1973	<u>London flu</u>	<u>Influenza</u>	[122]
15,000	<u>India</u>	1974	<u>1974 smallpox epidemic of India</u>	<u>Smallpox</u>	[123]
> 32,000,000	worldwide (commenced in <u>Congo Basin</u> )	1960–present	<u>HIV/AIDS pandemic</u>	<u>HIV/AIDS</u>	[124]
	<u>South America</u>	1990s		<u>Cholera</u>	
52	<u>India</u>	1994	<u>1994 plague epidemic in Surat</u>	<u>Plague</u>	[125]
231	worldwide	1996–2001		<u>vCJD</u>	
	<u>West Africa</u>	1996		<u>Meningitis</u>	
105	<u>Malaysia</u>	1998–1999	<u>1998–99 Malaysia Nipah virus outbreak</u>	<u>Nipah virus infection</u>	[126]
	<u>Central America</u>	2000		<u>Dengue fever</u>	[127]

**Table 6:** 20th Century.

Death toll (estimate)	Location	Date	Event	Disease	Ref.
> 400	<u>Nigeria</u>	2001		<u>Cholera</u>	[128]
	<u>South Africa</u>	2001		<u>Cholera</u>	[129]
349	<u>China</u>	2002–2004	<u>SARS outbreak</u>	<u>SARS coronavirus</u>	[130]
299	<u>Hong Kong</u>	2002–2004	<u>SARS outbreak</u>	<u>SARS coronavirus</u>	[131]
37	<u>Taiwan</u>	2002–2004	<u>SARS outbreak</u>	<u>SARS coronavirus</u>	[132]
44	<u>Canada</u>	2002–2004	<u>SARS outbreak</u>	<u>SARS coronavirus</u>	[133]
33	<u>Singapore</u>	2002–2004	<u>SARS outbreak</u>	<u>SARS coronavirus</u>	[134]
	<u>Algeria</u>	2003		<u>Plague</u>	[135]
	<u>Afghanistan</u>	2004		<u>Leishmaniasis</u>	[136]
	<u>Bangladesh</u>	2004		<u>Cholera</u>	[137]
	<u>Indonesia</u>	2004		<u>Dengue fever</u>	[138]
	<u>Senegal</u>	2004		<u>Cholera</u>	[139]
7	<u>Sudan</u>	2004		<u>Ebola</u>	[140]
	<u>Mali</u>	2005		<u>Yellow fever</u>	[141]
27	<u>Singapore</u>	2005	<u>2005 dengue outbreak in Singapore</u>	<u>Dengue fever</u>	[142]
	<u>Luanda, Angola</u>	2006		<u>Cholera</u>	[143]
61	<u>Ituri Province, Democratic Republic of the Congo</u>	2006		<u>Plague</u>	[167][168]
17	<u>India</u>	2006		<u>Malaria</u>	[169]
> 50	<u>India</u>	2006	<u>2006 dengue outbreak in India</u>	<u>Dengue fever</u>	[169]
	<u>India</u>	2006	<u>Chikungunya outbreaks</u>	<u>Chikungunya virus</u>	[170]
> 50	<u>Pakistan</u>	2006	<u>2006 dengue outbreak in Pakistan</u>	<u>Dengue fever</u>	[171]
	<u>Philippines</u>	2006		<u>Dengue fever</u>	[172]
187	<u>Democratic Republic of the Congo</u>	2007	<u>Mweka ebola epidemic</u>	<u>Ebola</u>	[173]
	<u>Ethiopia</u>	2007		<u>Cholera</u>	[174]
49	<u>India</u>	2008		<u>Cholera</u>	[175]
10	<u>Iraq</u>	2007	<u>2007 Iraq cholera outbreak</u>	<u>Cholera</u>	[176]
	<u>Nigeria</u>	2007		<u>Poliomyelitis</u>	[177]
	<u>Puerto Rico; Dominican Republic; Mexico</u>	2007		<u>Dengue fever</u>	[178]
	<u>Somalia</u>	2007		<u>Cholera</u>	[179]
37	<u>Uganda</u>	2007		<u>Ebola</u>	[180]
	<u>Vietnam</u>	2007		<u>Cholera</u>	[181]
	<u>Brazil</u>	2008		<u>Dengue fever</u>	[182]
	<u>Cambodia</u>	2008		<u>Dengue fever</u>	[183]
	<u>Chad</u>	2008		<u>Cholera</u>	[184]

Death toll (estimate)	Location	Date	Event	Disease	Ref.
	<u>China</u>	2008–2017		<u>Hand, foot and mouth disease</u>	[185]
	<u>Madagascar</u>	2008		<u>Bubonic plague</u>	[186]
	<u>Philippines</u>	2008		<u>Dengue fever</u>	[187]
	<u>Vietnam</u>	2008		<u>Cholera</u>	[188]
4,293	<u>Zimbabwe</u>	2008–2009	<u>2008–2009 Zimbabwean cholera outbreak</u>	<u>Cholera</u>	[189]
18	<u>Bolivia</u>	2009	<u>2009 Bolivian dengue fever epidemic</u>	<u>Dengue fever</u>	[190]
49	<u>India</u>	2009	<u>2009 Gujarat hepatitis outbreak</u>	<u>Hepatitis B</u>	[191]
	<u>Queensland, Australia</u>	2009		<u>Dengue fever</u>	[192]
	<u>Worldwide</u>	2009	<u>Mumps outbreaks in the 2000s</u>	<u>Mumps</u>	
931	<u>West Africa</u>	2009–2010	<u>2009–2010 West African meningitis outbreak</u>	<u>Meningitis</u>	[193]
203,000	<u>Worldwide</u>	2009	<u>2009 flu pandemic</u>	<u>Influenza</u>	[194][195]
9,985 (May 2017)	<u>Hispaniola</u>	2010–present	<u>Haiti cholera outbreak</u>	<u>Cholera</u>	[196][197]
> 4,500 (February 2014)	<u>Democratic Republic of the Congo</u>	2011–present		<u>Measles</u>	[198][199]
170	<u>Vietnam</u>	2011–present		<u>Hand, foot and mouth disease</u>	[200][201]
> 350	<u>Pakistan</u>	2011	<u>2011 dengue outbreak in Pakistan</u>	<u>Dengue fever</u>	[202]
171 (as of 10 January 2013)	<u>Darfur Sudan</u>	2012	<u>2012 yellow fever outbreak in Darfur, Sudan</u>	<u>Yellow fever</u>	[203]
862 (as of 13 January 2020)	<u>Worldwide</u>	2012–present	<u>2012 Middle East respiratory syndrome coronavirus outbreak</u>	<u>Middle East respiratory syndrome</u>	[204][205][206]
142	<u>Vietnam</u>	2013–2014		<u>Measles</u>	[207]
>> 11,300	<u>Worldwide, primarily concentrated in West Africa</u>	2013–2016	<u>Ebola virus epidemic in West Africa</u>	<u>Ebola virus disease</u> <u>Ebola virus virion</u>	[208][209][210]
183	<u>Americas</u>	2013–2015	<u>2013–14 chikungunya outbreak</u>	<u>Chikungunya</u>	[211]
40	<u>Madagascar</u>	2014–2017	<u>2014 Madagascar plague outbreak</u>	<u>Bubonic plague</u>	[212]
36	<u>India</u>	2014–2015	<u>2014 Odisha jaundice outbreak</u>	Primarily <u>Hepatitis E</u> , but also <u>Hepatitis A</u>	[213]
2,035	<u>India</u>	2015	<u>2015 Indian swine flu outbreak</u>	<u>Influenza A virus subtype H1N1</u>	[214][215][216]
~53	<u>Worldwide</u>	2015–2016	<u>2015–16 Zika virus epidemic</u>	<u>Zika virus</u>	[217]
100's (as of 1 April 2016)	<u>Africa</u>	2016	<u>2016 yellow fever outbreak in Angola</u>	<u>Yellow fever</u>	[218]
3,886 (as of 30 November 2019)	<u>Yemen</u>	2016–present	<u>2016–17 Yemen cholera outbreak</u>	<u>Cholera</u>	[219]
64 (as of 16 August 2017)	<u>India</u>	2017	<u>2017 Gorakhpur Japanese encephalitis outbreak</u>	<u>Japanese encephalitis</u>	[220]
18 (as of February 2020)	<u>India</u>	2018	<u>2018 Nipah virus outbreak in Kerala</u>	<u>Nipah virus infection</u>	[221]

Death toll (estimate)	Location	Date	Event	Disease	Ref.
2,253 (as of 20 February 2020)	<u>Democratic Republic of the Congo &amp; Uganda</u>	August 2018–present	<u>2018–19 Kivu Ebola epidemic</u>	<u>Ebola virus disease</u>	[222][223]
>6,000 (by January 2019)	<u>Democratic Republic of the Congo</u>	2019–present	<u>2019 measles outbreak in the Democratic Republic of the Congo</u>	<u>Measles</u>	[224]
83	<u>Samoa</u>	2019–present	<u>2019 Samoa measles outbreak</u>	<u>Measles</u>	[225]
3,360 (as of 6 March 2020)	<u>Worldwide</u>	2019–present	<u>2019–20 coronavirus outbreak</u>	<u>COVID-19</u>	[226][227]

**Table 7:** 21st Century.

Coronaviruses are a group of viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that are typically mild, such as some cases of the common cold (among other possible causes, predominantly rhinoviruses), though rarer forms can be lethal, such as SARS, MERS, and COVID-19. Symptoms vary in other species: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. Coronaviruses constitute the subfamily Orthocoronavirinae, in the family Coronaviridae, order Nidovirales, and realm Ribavirin. [31] [32] They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry. The genome size of coronaviruses ranges from approximately 27 to 34 kilobases, the largest among known RNA viruses [33].

### Evolution

The most recent common ancestor (MRCA) of all coronaviruses has been placed at around 8000 BCE. [34] The MRCAs of the Alpha-coronavirus line has been placed at about 2400 BCE, the Beta-coronavirus line at 3300 BCE, the Gamma-coronavirus line at 2800 BCE, and the Delta-coronavirus line at about 3000 BCE. It appears that bats and

### Discussions and Results

By mentioning all the facts, evolution and all the similarities from the viruses, we observe that all kinds of Flu including COVID-19 which have been caused many deaths through epidemic and pandemic of these giant but very small

birds, as warm-blooded flying vertebrates, are ideal hosts for the coronavirus gene source (with bats for Alpha-coronavirus and Betacoronavirus, and birds for Gamma-coronavirus and Delta-coronavirus) to fuel coronavirus evolution and dissemination.[35] Bovine coronavirus and canine respiratory coronaviruses diverged from a common ancestor in 1951.[36] Bovine coronavirus and human coronavirus OC43 diverged around the 1890s. Bovine coronavirus diverged from the equine coronavirus species at the end of the 18th century.[37] The MRCA of human coronavirus OC43 has been dated to the 1950s.[38] MERS-CoV, although related to several bat coronavirus species, appears to have diverged from these several centuries ago.[39] The human coronavirus NL63 and a bat coronavirus shared an MRCA 563–822 years ago.[40] The most closely related bat coronavirus and SARS-CoV diverged in 1986.[41] A path of evolution of the SARS virus and keen relationship with bats have been proposed. The coronaviruses have been coevolved with bats for a long time and the ancestors of SARS-CoV first infected the species of the genus Hipposideridae, subsequently spread to species of the Rhinolophidae and then to civets, and finally to humans. [42] [43] Alpaca coronavirus and human coronavirus 229E diverged before 1960 [44].


objects, all the viruses from the first one before the rise of the human in evolution, had been existed. Through my deep research, the first virus was or blue-green algae, pre-date viruses and are one of the oldest forms of life on Earth.



**Picture 4:** Blue-green algae, pre-date viruses and are one of the oldest forms of life on Earth.

The researchers developed algorithms to compare the protein shapes of 3,460 viruses and 1,620 cells. They found that 442 protein folds were shared between cells and viruses, but 66 folds were unique to viruses. To make sense of the data, the team arranged the protein folds into a tree that grew a new 'branch' every time a new type of protein fold evolved. Wherever possible, the team used fossil evidence to put an approximate date on the budding of specific branches. For example, one particular protein fold was first seen in cyanobacteria (blue-green algae), and later appeared in all its descendants. By comparing when cyanobacteria first appeared in the fossil record (2.1 billion years ago) to when its offspring later emerged, they could establish this particular fold appeared around 2 billion years ago. According to Caetano-Anollés's microbial family tree, viruses are ancient, however; they were not the first form of life. In fact, his family tree suggests viruses and bacteria share a common ancestor – a fully functioning, self-

replicating cell that lived around 3.4 billion years ago, shortly after life first emerged on the planet. From this cell, bacteria have evolved in the direction of increasing complexity, while viruses have gradually shed genes they found they didn't need, until they could no longer even reproduce on their own. A key step in the virus evolutionary journey seems to have come about around 1.5 billion years ago and that's the age at which the 66 virus-specific protein folds came on the scene. These changes are to proteins in the virus' outer coat – the machinery viruses use to break into host cells. For Charleston, the remarkable point about the study is how many proteins today's bacteria and viruses have in common. [Arshan Nasir, Kyung Mo Kim, Gustavo Caetano-Anollés, *Viral evolution, Primordial cellular origins and late adaptation to parasitism, Mob Genet Elements*. 2012 Sep 1; 2(5): 247–252. doi: 10.4161/mge.22797].



**Picture 6:** The origin of the viruses was before the beginning the cellular ancestor of any species. Based on picture (5) and the mentioned era of the virus evolution, they have been there since 3.5 billion years ago when cyanobacteria begin to be existed [Soroush Niknamian et al, 2017]. The main problem is to find what or which kinds of matter can fight this machine-like organism.


### Drift

New viruses can also emerge by drift. Drift can refer to genetic drift or antigenic drift. [45] Mutation and selection for the most advantageous variation of the virus takes place during this form of evolution. Natural Selection and Lamarckian Evolution both caused the evolution of several

viruses like Coronaviruses fast enough. [45] Antigenic mutants can evolve quickly due to the high mutation rate in viruses. The cause of the antigenic drift lies in the mechanisms of RNA synthesis itself. Mutations arise very easily simply due to the error prone RNA polymerase and

its lack of proofreading mechanisms. These mutations lead to subtle changes in the HA and NA genes which completely changes the infectious capabilities of the virus. These changes allow for almost endless possibilities for new viral strains to arise [46] and it is the antigenic drift of the HA and NA genes that allow for the virus to infect humans that receive vaccines for other strains of the virus. [48] This evolution occurs under the pressure of antibodies or immune system responses. Seven strains of human coronaviruses are known and four of them produce the generally mild symptoms of the common cold: 1) Human

coronavirus OC43 (HCoV-OC43), 2) Human coronavirus HKU1, 3) Human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), 4) Human coronavirus 229E (HCoV-229E) and three coronaviruses that are potentially fatal: 5) Middle East respiratory syndrome-related coronavirus (MERS-CoV), previously known as novel coronavirus 2012 and HCoV-EMC, 6) Severe acute respiratory syndrome coronavirus (SARS-CoV or "SARS-classic"), 7) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019-nCoV or "novel coronavirus 2019" [45].



**Picture 7:** An antigenic shift, or Reassortment, which has the main result of novel and highly pathogenic strains of SARS-CoV-2 and other DNA and RNA viruses like All types of fatal Influenza

### Reassortment

Reassortment, also known as antigenic shift, allows new viruses to evolve under both natural conditions and in artificial cultures. [45] Reassortment occurs in a similar way as chromosome crossover events, as two different viral strains may come in contact and transfer some of their genetic information. This crossing-over event creates a mixture of the two viral strains, which may replicate as one hybrid virus that expresses traits from both original viruses. [46] The mechanism of the evolutionary force of antigenic shift allows influenza viruses to exchange genes with strains that infect different species. Under this mechanism, a human influenza virus could exchange genes with an avian strain, and that is how pandemic strains arise. There have been three occurrences of pandemics caused by antigenic shift since 1900, and it has happened again today as we know as SARS-CoV-2. [47] In fact, the 1957 evolution of the H2N2 virus is thought to be a result of Reassortment. [45] In this case, human H1N1 strains and avian influenza A genes were mixed. [45] Infecting tissue cultures can demonstrate how pathogenic qualities can evolve for a particular species even though the reassorted virus may be nonpathogenic for another species. [45] A prime example of evolution under natural conditions is the Reassortment

of two avian influenza strains that were discovered in dead seals back in 1979 [45].

Based on research by Fairchild GA. 1977, Inhalation of ozone and sulfur dioxide inhibited influenza virus growth in the nose of mice. Ozone inhalation caused the more pronounced inhibition of influenza virus growth: 0.6 ppm ozone for 3 hours' post-virus exposure almost completely inhibited influenza virus growth in the nose, whereas sulfur dioxide (6 ppm for 7 days) causes only partial inhibition of influenza virus growth in the nose. Neither gas altered the propagation of influenza virus in the lungs of mice. Vesicular stomatitis virus (VSV) growth was either unaffected by exposure to ozone (0.9 ppm for 3 hours) or, when ozone exposure preceded VSV exposure, the virus may have grown to slightly higher titer. The inhibitory effect of ozone and sulfur dioxide on influenza virus growth in nasal epithelium suggests a competitive interaction between the chemical inhalant, the virus, and host tissues, with net consequences for the pathogenesis of this disease. If the effects of these inhalants are to be properly interpreted, they should be determined for all major regions of virus growth and inhalant deposition. [Fairchild GA., 1977]. Therefore; inhalation of Ozone plus Sulfur Dioxide may inhibit the influenza virus growth in humans as well.


Another research in 1947 by Harry M. Rose and Alfred Gellhorn indicated that Influenza virus was rendered noninfectious for mice by in vitro exposure to relatively high concentrations of sulfur and nitrogen mustards. Concentrations of the mustards that abolished infectivity did not reduce the ability of the virus to agglutinate erythrocytes. The parenteral administration of nitrogen mustard had no effect on the course of infection with influenza virus in mice. [Harry M. Rose et al., 1947].

There are several researches on the compound L-Glutathione which contains high sulfur amounts and it is normally produced by liver but the amounts vary in ages and sexes in its compound and inhibits viral infection. [Juliana Echevarria Lima, 2918] [Palamara AT. Et al 1995] [Pietro Ghezzi, 2911] [Jing An, 2013] [Pål Aukrust et al. 2003] [ANNA TERESA PALAMARA et al. 2009] [A. Fraternali et al. 2006] [Henry Jay Forman et al., 2009] [Katia Aquilano et al., 2014] [Mohammad Latif Reshi et al, 2014]. These researches has done in in Vivo and in Vitro with controlled groups double blind and received totally positive results and the treatment of the patients with several most dangerous viral diseases including Coronaviruses.


### Sulfur and Viruses

Scientists have known about viruses that attack bacteria since the early twentieth century. In 1917, Felix d'Herelle, a


French-Canadian microbiologist, and his colleagues successfully isolated phages that kill bacteria like E. coli, salmonella, and dysentery, and doctors used his so-called phage therapies to treat disease. But phage research lost steam in the 1950s in the face of penicillin and other powerful new antibiotics. Bacteria are living micro-organism which can be affected by viruses. The adaptation of bacteria to fight viruses are higher than human living cells. Therefore; this is the most important research on Phages against viruses which should be considered by scientists to fight against all viruses including 2019-Coronavirus. Paula Dalcin Martins and his colleagues reached positive results using Sulfur against many viruses. [Paula Dalcin Martins et al. 2018]. Basically, if two viruses share a good number of genes, they are probably related like MERS, SARS and 2019-Coronavirus. The fewer genes they share, the more divergent their evolutionary paths. The most impressive article about sulfur against viruses has been published by Matthew B Sullivan which indicated Sulfur can kill and terminate any known viruses in eukaryotic host cells. [Matthew B Sullivan et al., 2015] Based on Felix d'Herelle and Matthew B Sullivan statements and articles, Sulfur and Phage Therapies can be one of the main treatment of viral diseases through coevolution hypothesis (coevolution occurs when two or more species reciprocally affect each other's evolution through the process of natural selection like viruses and mammals.) including SARS-CoV-2.




**Picture 8:** Diagram of coronavirus Virion structure.



**Picture 9:** Illustration of a SARS-CoV-2 Virion



**Picture 10:** MERS virus, Middle-East Respiratory Syndrome Coronavirus Virion, (Camel Flu).



**Picture 11:** A typical virus replication cycle including Sars-Cov-2019. 2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus. Although our phylogenetic analysis suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans. Importantly, structural analysis suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans. The future evolution, adaptation, and spread of this virus warrant urgent investigation. [Lu G Hu Y Wang Q et al.] [Wang N Shi X Jiang L et al.] [Waterhouse A Bertoni M Bienert S et al].

In Taxonomy, the family Coronaviridae is organized in 2 sub-families, 5 genera, 23 sub-genera and about 40 species: [2]: Coronaviridae - Orthocoronavirinae - Letovirinae - Alphaletovirus - Milecovirus and then Microhyala letovirus 1 [3].

MERS-CoV and Severe acute respiratory syndrome (SARS) are betacoronavirus derived from bats. [2] Between November 2002 and July 2003, an outbreak of SARS in southern China caused an eventual 8,098 cases, resulting in 774 deaths reported in 17 countries (9.6% fatality rate), with the majority of cases in mainland China and Hong Kong. No cases of SARS have been reported worldwide since 2004. In late 2017. [1-3] Chinese scientists traced the virus through the intermediary of civets to cave-dwelling horseshoe bats in Yunnan province. [228] Therefore; through the lines above, SARS and COVID-19 outbreak was first observed in China. The coronaviruses HCoV-229E, -

NL63, -OC43, and -HKU1 continually circulate in the human population and cause respiratory infections in adults and children world-wide [229].

In the new Coronavirus, Genetic recombination which is the process by a strand of DNA that is broken and then joined to the end of a different DNA molecule. This can occur when viruses infect cells simultaneously and studies of viral evolution have shown that recombination has been rampant in the species studied. [230]. Recombination is common to both RNA and DNA viruses. [231] [108] SARS-CoV-2 has undergone genetic change by several mechanisms. These include a antigenic drift process where individual bases in the RNA mutate to other bases. the mutations of this virus is silent means it does not change the protein that the gene encodes. And confers evolutionary advantages such as resistance to antiviral drugs. [230-234].



Therefore; we cannot mention there would be any possible antiviral drugs to resist this kind of virus even in the future. SARS-CoV-2 is an RNA Virus. its nucleic acid is single-stranded RNA (ssRNA). The polarity of this virus is positive-sense ((+) ssRNA). Positive-sense viral RNA is similar to mRNA and thus can be immediately translated by the host cell. Recombination in RNA viruses appears to be an adaptation for coping with genome damage. Recombination can occur infrequently between animal viruses of the same species but of divergent lineages. The resulting recombinant viruses may sometimes cause an outbreak of infection in humans. RNA viruses have very high mutation rates. This is one reason why it is difficult to make effective vaccines to prevent diseases caused by RNA viruses [235] [236].

### Mathematical Calculation of SARS-CoV-2 and Future Concerns

The Factorial formula is:

#### ***Factorial Formula***

Factorial formula by **Product**


$$n! = \prod_{k=1}^n k$$

Factorial Formula by **Recurrence Relation**

$$n! = \begin{cases} 1 & \text{if } n = 0, \\ (n - 1)! * n & \text{if } n > 0 \end{cases}$$

The size of SARS-CoV-2 is approximately 0.3 microns [237]. With conversion of Micrometer into nanometer, 0.3 will be 300 nm in size. In page 21, we have described the Antigenic Drift of viruses especially SARS-CoV-2. The mathematical calculation of how many types of this virus exists is:  $3 \times 4$ , since we have 4 types of mild coronavirus and 3 types of

deadly with severe symptoms. So the numbers of different coronaviruses will be  $3 \times 4 = 12$ . Therefore; based on each type of virus is different from another one, we use Factorial to measure all types of coronavirus which exists on earth till now without the concern of the mutation in vivo of the virus. It is  $12! = 479001600$ . Overall, the number of different SARS-CoV-2 is about 479001600. Each of these kinds of viruses when get inside their hosts also mutates. Therefore; Each of these coronaviruses get inside their host will have different symptoms from mild into severe based on the host's immune system response and other factors. Hence; all these SARS-CoV-2, will mutate and possible severe symptoms will occur based on the Reassortment of the virus which have been described in page 22. The probability of each person in the world who may contaminate with this virus is 7.8 Billion/479001600 equals 16.2838704505. This is the probability from the first time outbreak of the virus means approximately 16% of the population infected by the virus. So the near future of death or infected people from SARS-CoV-2 will be 1248000000. Based on high rates of mutation of 2019-Corovirus, each carrier of this deadly virus may/will contaminate another living human. Therefore; all people will carry this virus in the near future. We do not know the time range of this highly pandemic, but the lesson that we have learnt from the history is that the only way to fight the virus will not produce new vaccines, since the adaptation and the mutation of the virus is higher than any known ones on earth. The only answer to end the pandemic, is the adaptation of human race to SARS-CoV-2 through Lamarckian Evolution. This infectious disease with 7.8 billion people living on earth is like playing with dices and the people contamination is random in mathematical Theorems. Some may adapt to the virus, some will die and the rest will be the carrier, therefore; the graph we predict is like the bean machine, a device invented by Francis Galton shown below:



**Picture 12:** The bean machine, a device invented by Francis Galton, can be called the first generator of normal random variables. This machine consists of a vertical board with interleaved rows of pins. Small balls are dropped from the top and then bounce randomly left or right as they hit the pins. The balls are collected into bins at the bottom and settle down into a pattern resembling the Gaussian curve.

According to the central limit theorem (more specifically, the de Moivre–Laplace theorem), the binomial distribution approximates the normal distribution provided that the number of rows and the number of balls are both large. Varying the rows will result in different standard deviations or widths of the bell-shaped curve or the normal distribution in the bins. [238] [239].

### 2019-Corovirus Relation to Fibonacci Sequence


The Fibonacci numbers, commonly denoted  $F_n$ , is a function called the Fibonacci sequence, means each number is the sum of the two preceding numbers, starting from 0 and 1:

$$F_0 = 0, \quad F_1 = 1, \\ F_n = F_{n-1} + F_{n-2},$$


And the sequence is: 0, 1, 1, 2, 3, 5, 8, 13, 21, 34, 55, 89, 144, ...

We have collected the infected people with COVID-19. If we suppose each infected individual infects one other individual each day and at the end of day-two recovers fully or dies (we are interested in the number of people who are actively infected and alive). So the time stamps are the beginning of day-one, at the end of day-one and at


the end of day-two. According to our model, an infected individual can infect one other person at the end of day-one and at the end of day-two. If we go on through time (days), the table below shows the result of infected people:



**Picture 13:** The right vertical numbers shows the infected people per day.



**Picture 14:** The number of infected people through time (day) by COVID-19.



**Picture 15:** The Graph of Fibonacci and Pandemic of COVID-19.

Therefore; the formula of infected people per day is:  $F_n = F_{n-1} + F_{n-2}$  (for  $n > 2$ ), which is the formula of Fibonacci series.

### Viruses Related to COVID-2019

There are some viruses that causes respiratory infection. Enteroviruses, Poliovirus, coxsackie, echovirus and Human orthopneumovirus. Hence; none of them has been related to 2019-Coronavirus. Since their Signs and symptoms, Structure, Genome, Evolution, Taxonomy and Transmission are not similar to the new COVID-2019. The only virus that has been correlated with COVID-2019 is Rhinovirus. The rhinovirus is the most common viral infectious agent in humans and is the predominant cause of the common cold and flu. Rhinovirus infection proliferates in temperatures of 33–35 °C (91–95 °F), the temperatures found in the nose. The three species of rhinovirus (A, B, and C) include around 160 recognized types of human rhinovirus that differ according to their surface proteins (serotypes) They are lytic in nature and are among the smallest viruses, with diameters of about 30 nanometers. By comparison, other viruses, such as smallpox and vaccinia, are around ten times larger at about 300 nanometers (the same diameter as COVID-2019 which is 300 nanometers in size). [240] There are two modes of transmission: via aerosols of respiratory droplets and from fomites (contaminated surfaces), including direct person-to-person contact. Rhinoviruses are spread worldwide and are the primary cause of the common cold. Symptoms include sore throat, runny nose, nasal congestion, sneezing and cough. Those most affected by rhinoviruses are infants, the elderly, and immune compromised people (Most elderly and Children). Human rhinoviruses preferentially grow at 32 °C (89 °F), notably colder than the average human body temperature of 37 °C (98 °F); hence the virus's tendency to infect the upper respiratory tract, where respiratory airflow is in continual contact with the (colder) extrasomatic environment. [241] Rhinoviruses have single-stranded positive sense RNA genomes of between 7200 and 8500 nt in length. At the 5'

end of the genome is a virus-encoded protein, and like mammalian mRNA, there is a 3' poly-A tail. Structural proteins are encoded in the 5' region of the genome and nonstructural at the 3' end. This is the same for all picornaviruses. The viral particles themselves are not enveloped and are icosahedral in structure. The viral proteins are translated as a single, long polypeptide, which is cleaved into the structural and nonstructural viral proteins. [242] Human rhinoviruses are composed of a capsid that contains four viral proteins, VP1, VP2, VP3 and VP4. VP1, VP2, and VP3 form the major part of the protein capsid. The much smaller VP4 protein has a more extended structure and lies at the interface between the capsid and the RNA genome. There are 60 copies of each of these proteins assembled as an icosahedron. Antibodies are a major defense against infection with the epitopes lying on the exterior regions of VP1-VP3. Human rhinovirus is most contagious during the autumn and winter months. The virus can remain activated for up to 3 hours outside of a human host. Once the virus is contracted, a person is most contagious within the first 3 days. Preventive measures such as regular vigorous hand washing with soap and water may aid in avoiding infection. Avoiding touching the mouth, eyes and nose, the most common entry points for rhinovirus, may also aid in prevention. Droplet precautions, which take the form of a surgical mask and gloves, is the method used in major hospitals. [243] [244] [245] As mentioned, through our analysis, the most related virus to COVID-2019, is Rhinovirus which has very similar in Structure, Genome, Size and symptoms of the SARS-CoV-2. There has not been an effective anti-viral vaccination of this virus either. There is a high possibility of mutation in this virus into 2019-Coronavirus. In 2018, a new series of anti-rhinoviral compounds were reported by researchers at Imperial College London and colleagues at the University of York and the Pirbright Institute. These molecules target

human N-myristoyltransferase, an enzyme in the host cell which picornavirus requires in order to assemble its viral capsid, and thus generate an infectious virion. The lead compound in this series, IMP-1088, very potently inhibited host myristoylation of viral capsid protein and prevented infectious virus formation, rescuing the viability of cells in culture which had been exposed to a variety of rhinovirus serotypes, or to related picornaviruses including poliovirus and foot-and-mouth-disease virus. Because these compounds target a host factor, they are broadly active against all serotypes, and it is thought to be unlikely that they can be overcome by resistance mutations in the virus [246] [247] [248].

### The main Cause of COVID-19 Pandemic

Through the lines and statements in this article, we hypothesize that the prime cause of SARS-CoV-2 is: [1] The coevolution and Red Queen effect between mammals including humans and viruses. coevolution occurs when two or more species reciprocally affect each other's evolution through the process of natural selection and the Red Queen effect which is an evolutionary hypothesis that proposes organisms must constantly adapt, evolve, and proliferate in order to survive while pitted against ever-evolving opposing organisms in a constantly changing environment, as well as to gain reproductive advantage. Increasing human population, antibiotic resistance, antiviral resistance, malnutrition, immune deficiency (basically nutrition low in sulfur), low adaptation of human in their environment (Lamarckian Evolution) and high adaptation of viruses with human genome [249-252].

[2] The main cause of SARS-CoV-2 is through natural selection and Lamarckian Evolution Both which caused this RNA virus so powerful and different in the nations worldwide. The first Pandemic of Influenza was detected in 1732 and this virus evolved through natural selection till 2019 through Drift and Reassortment of SARS-CoV-1 and Influenza viruses which caused the worldwide pandemic of SARS-CoV-2. [45] [46] There may be a correlation between Rhinoviruses and COVID-19 which has not been studied yet and should be considered [240].

### The Possible Treatment of COVID-19 (SARS-CoV-2)

Based on our research/Review of many major researches, there has not been any antiviral vaccines against these viruses and no antiviral drugs will be useful against COVID-19 since the adaptation and high mutation of this virus will not let these drugs be effective. The prime possible treatment Inhalation of ozone and sulfur dioxide, increasing L-Glutathione Plus Viral Phage Therapy (VFT) is the possible prime treatment of this disease. Finding the right Phage Therapy is very hard in any viral infections since this therapy was mainly used against bacterial infections. However; through our research and findings we have concluded that substantial dose-dependent inhibition by T4 phage of adsorption of HAdV to both A549 and HEK293 cell lines in vitro LPS was without effect. Moreover, T4 phage protected A549 cells from an HAdV-induced cytopathic effect (Międzybrodzki et al., 2013; Przybylski et al., 2015). These data suggest that T4 phage could be

considered as a potential novel antiviral agent. The capacity of the phage to inhibit HAdV infection at the stage of viral replication suggests that phage could also interfere with viruses using cellular receptors other than those used by HAdV. Notably, the anti-viral effect of phage was measured as the decrease of the end-point HAdV infectious titer. Further in vitro studies were carried out on the effects of T4 and the staphylococcal phage A5/80 on HAdV DNA synthesis (real-time PCR) and the expression of its early and late genes (measured at the level of mRNA synthesis) in an A549 cell culture. Continuous incubation of adenovirus-infected cells with T4 phage significantly reduced the level of adenoviral DNA synthesis (this effect was not observed with the staphylococcal phage). Coincubation with a high titer of T4 phage was required for inhibition of HAdV early gene expression. Late adenoviral gene expression was reduced by preincubation (application of phage prior to HAdV infection) and Coincubation with both phages when a low HAdV titer was used. In contrast, when a high HAdV titer was applied, both incubation and preincubation with T4 phage were inhibitory whilst a staphylococcal phage was inhibitory only when continuous incubation with cells was applied. Those results suggest that the inhibitory effect of phage on HAdV infection may differ and may be partially explained by their influence on the expression of early and late adenoviral genes (Przybylski et al., 2018). When the effect of both phages on the expression of genes involved in antimicrobial immunity by the A549 cell line from human lung was studied, the most striking phenomenon was marked (>10-fold) enhancement of a gene coding for interleukin-2 (Il-2) by a staphylococcal phage (Borysowski et al., 2018). This effect is of particular interest in the context of the well-known role of NK cells in the immune response to viruses (Hammer et al., 2018) and the ability of Il-2 to induce those cells – even in ultra-low doses (Fehniger et al., 2000; Ito et al., 2014). Interestingly, a resident NK cell population is present in the human lung and may provide early and important control of viral infection (Cooper et al., 2018). Moreover, NK cells also exhibit activity against a variety of bacteria, e.g., by secretion of the soluble molecules perforin and granulysin. Mice infected with *Shigella* and lacking B and T cells but with normal NK cells have higher survival rates and lower bacterial titers than mice which lack all three cell types. This suggests that phage-induced Il-2 dependent activation of NK-mediated antimicrobial activity may contribute to beneficial effects of PT, especially during prolonged phage administration cumulative median duration of successful phage therapy is 43 days (Międzybrodzki et al., 2012). NK cells could be a promising agent in antimicrobial immunotherapy, as data strongly suggest that these cells are active against not only viral but also bacterial and fungal pathogens (Schmidt et al., 2018).

### Acknowledgements

We would like to thank Senator Mark R Warner, Senator Tim Kaine and Representative Ben Cline for their inspirational help and dedication their time and help to the United States of America. Also, we would like to thank Mrs. Fallon Morell the President of Weston A Price Foundation (WAPF), Professor Stephanie Seneff (senior research

scientist at the Computer Science and Artificial Intelligence Laboratory (CSAIL), Massachusetts Institute of Technology), Professor Thomas N Seyfried (Morrissey College of Arts and Sciences) and Professor Dominic D'Agostino (Research Scientist, Inst. Human and Machine Cognition, Professor, College of Medicine Molecular Pharmacology & Physiology, Morsani College of Medicine, Molecular Pharmacology & Physiology for their motivational help in my beginning of our first research till now.

## Conclusion

In this Research/Review articles, we have gone through all the cases and epidemic of all the fatal diseases from the first time mentioned in history including Flu/Influenza pandemic until 2020. Based on our research, the only period of time when there was no outbreak of influenza, RNA viruses or infectious diseases were during World War 2, where German scientists controlled the epidemic of any virus infections which should be noted by the scientists and researchers. The mutation of the SARS-CoV and Influenza viruses is the main cause of SARS-CoV-2 through natural selection and Lamarckian Evolution Both which caused this RNA virus so powerful and different in the nations worldwide. The first Pandemic of Influenza was first detected in 1732 and this virus evolved through natural selection till 2019 which caused the worldwide pandemic of SARS-CoV-2. Based on many studies, inhalation of Ozone plus Sulfur Dioxide, increasing the amounts of L-Glutathione (Which is low in children and older adults) plus Viral Phage Therapy (VPT) can be the prime treatment of SARS-CoV-2 infection. The seasonal temperature cannot be useful in controlling or reducing the pandemic of this virus since the temperature rises gradually and the natural selection, Lamarckian Evolution and high mutation rate of the virus helps its survival. In our mathematical calculation, the number of infected people is/will be 1248000000 which should not be ignored by the scientists. We also introduced the Fibonacci Model in calculating the infected/will be infected people. Through our research we have found that no antiviral drugs will be useful against SARS-CoV-2 because of high rate of mutation and adaptation of the virus to the drugs and even the environment temperature.

## References

1. McMichael AJ (2004). "Environmental and social influences on emerging infectious diseases: past, present and future". *Philosophical Transactions of the Royal Society B*. 359 (1447): 1049–1058. doi:10.1098/rstb.2004.1480. PMC 1693387. PMID 15306389.
2. Clark, p. 56
3. Barrett and Armelagos, p. 28
4. Villarreal, p. 344
5. Hughes AL, Irausquin S, Friedman R (2010). "The evolutionary biology of poxviruses". *Infection, Genetics and Evolution*. 10 (1): 50–59. doi:10.1016/j.meegid.2009.10.001. PMC 2818276. PMID 19833230.
6. Georges AJ, Matton T, Courbot-Georges MC (2004). "[Monkey-pox, a model of emergent then reemergent disease]". *Médecine et Maladies Infectieuses (in French)*. 34 (1): 12–19. doi:10.1016/j.medmal.2003.09.008. PMID 15617321.
7. Tucker, p. 6
8. Clark, p. 20
9. Barker, p. 1
10. a b Gibbs AJ, Ohshima K, Phillips MJ, Gibbs MJ (2008). Lindenbach B (ed.). "The prehistory of potyvirus: their initial radiation was during the dawn of agriculture". *PLoS ONE*. 3 (6): e2523. Bibcode:2008PLoSO...3.2523G. doi:10.1371/journal.pone.0002523. PMC 2429970. PMID 18575612.
11. Fargette D, Pinel-Galzi A, Sérémé D, Lacombe S, Hébrard E, Traoré O, Konaté G (2008). Holmes EC (ed.). "Diversification of rice yellow mottle virus and related viruses spans the history of agriculture from the neolithic to the present". *PLoS Pathogens*. 4 (8): e1000125. doi:10.1371/journal.ppat.1000125. PMC 2495034. PMID 18704169.
12. Zeder MA (2008). "Domestication and early agriculture in the Mediterranean Basin: origins, diffusion, and impact". *Proceedings of the National Academy of Sciences of the United States of America*. 105 (33): 11597–11604. Bibcode:2008PNAS...10511597Z. doi:10.1073/pnas.0801317105. PMC 2575338. PMID 18697943.
13. McNeill, p. 71
14. Baker, pp. 40–50
15. McNeill, p. 73
16. Clark, p. 57–58
17. Crawford (2000), p. 225
18. White DW, Suzanne Beard R, Barton ES (2012). "Immune modulation during latent herpesvirus infection". *Immunological Reviews*. 245 (1): 189–208. doi:10.1111/j.1600-065X.2011.01074. x. PMC 3243940. PMID 22168421.
19. Martin, P; Martin-Granel E (June 2006). "2,500-year evolution of the term epidemic". *Emerg Infect Dis*. 12 (6): 976–80. doi:10.3201/eid1206.051263. PMC 3373038. PMID 16707055
20. "Influenza (Seasonal)". World Health Organization (WHO). 6 November 2018. Archived from the original on 30 November 2019. Retrieved 30 November 2019.
21. Longo DL (2012). "Chapter 187: Influenza". *Harrison's principles of internal medicine (18th ed.)*. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
22. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. (2011). "Physical interventions to interrupt or reduce the spread of respiratory viruses" (PDF). *Cochrane Database Syst Rev* (7): CD006207. doi:10.1002/14651858.CD006207.pub4. PMC 6993921. PMID 21735402.

23. "Up to 650 000 people die of respiratory diseases linked to seasonal flu each year". World Health Organization (WHO) (Press release). 14 December 2017. Archived from the original on 18 April 2019. Retrieved 24 September 2019.
24. "Key Facts About Influenza (Flu)". Centers for Disease Control and Prevention (CDC). 9 September 2014. Archived from the original on 2 December 2014. Retrieved 26 November 2014.
25. Duben-Engelkirk PG, Engelkirk J (2011). *Burton's microbiology for the health sciences* (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 314. ISBN 978-1-60547-673-5.
26. "Types of Influenza Viruses Seasonal Influenza (Flu)". Centers for Disease Control and Prevention (CDC). 27 September 2017. Retrieved 28 September 2018.
27. Su S, Fu X, Li G, Kerlin F, Veit M (25 August 2017). "Novel Influenza D virus: Epidemiology, pathology, evolution and biological characteristics". *Virulence*. 8 (8): 1580–91. doi:10.1080/21505594.2017.1365216. PMC 5810478. PMID 28812422.
28. Picture 2 references:
29. Call S, Vollenweider M, Hornung C, Simel D, McKinney W (2005). "Does this patient have influenza?". *JAMA*. 293 (8): 987–97. doi:10.1001/jama.293.8.987. PMID 15728170.
30. "Flu Symptoms & Diagnosis". Centers for Disease Control and Prevention (CDC). 10 July 2019. Retrieved 24 January 2020.
31. "Flu Symptoms & Complications". Centers for Disease Control and Prevention (CDC). 26 February 2019. Retrieved 6 July 2019.
32. de Groot RJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, Perlman S, Poon L, Rottier PJ, Talbot PJ, Woo PC, Ziebuhr J (2011). "Family Coronaviridae". In King AM, Lefkowitz E, Adams MJ, Carstens EB, International Committee on Taxonomy of Viruses, International Union of Microbiological Societies. Virology Division (eds.). *Ninth Report of the International Committee on Taxonomy of Viruses*. Oxford: Elsevier. pp. 806–28. ISBN 978-0-12-384684-6.
33. International Committee on Taxonomy of Viruses (24 August 2010). "ICTV Master Species List 2009 – v10" (xls).
34. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR (August 2016). "Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens". *Journal of Virology*. 90 (16): 7415–28. doi:10.1128/JVI.00080-16. PMC 4984655. PMID 27279608. CoVs also have the largest known RNA virus genomes, ranging from 27 to 34 kb (31, 32), and increased fidelity in CoVs is likely required for the maintenance of these large genomes (14).
35. Wertheim JO, Chu DK, Peiris JS, Kosakovsky Pond SL, Poon LL (June 2013). "A case for the ancient origin of coronaviruses". *Journal of Virology*. 87 (12): 7039–45. doi:10.1128/JVI.03273-12. PMC 3676139. PMID 23596293.
36. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, et al. (April 2012). "Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus". *Journal of Virology*. 86 (7): 3995–4008. doi:10.1128/JVI.06540-11. PMC 3302495. PMID 22278237.
37. Bidokhti MR, Trávén M, Krishna NK, Munir M, Belák S, Alenius S, Cortey M (September 2013). "Evolutionary dynamics of bovine coronaviruses: natural selection pattern of the spike gene implies adaptive evolution of the strains". *The Journal of General Virology*. 94 (Pt 9): 2036–49. doi:10.1099/vir.0.054940-0. PMID 23804565.
38. Vijgen L, Keyaerts E, Moës E, Thoelen I, Wollants E, Lemey P, et al. (February 2005). "Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event". *Journal of Virology*. 79 (3): 1595–604. doi:10.1128/jvi.79.3.1595-1604.2005. PMC 544107. PMID 15650185.
39. Lau SK, Lee P, Tsang AK, Yip CC, Tse H, Lee RA, et al. (November 2011). "Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination". *Journal of Virology*. 85 (21): 11325–37. doi:10.1128/JVI.05512-11. PMC 3194943. PMID 21849456.
40. Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, et al. (August 2013). "Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus". *Journal of Virology*. 87 (15): 8638–50. doi:10.1128/JVI.01055-13. PMC 3719811. PMID 23720729.
41. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, et al. (December 2012). "Evidence supporting a zoonotic origin of human coronavirus strain NL63". *Journal of Virology*. 86 (23): 12816–25. doi:10.1128/JVI.00906-12. PMC 3497669. PMID 22993147.
42. Vijaykrishna D, Smith GJ, Zhang JX, Peiris JS, Chen H, Guan Y (April 2007). "Evolutionary insights into the ecology of coronaviruses". *Journal of Virology*. 81 (8): 4012–20. doi:10.1128/jvi.02605-06. PMC 1866124. PMID 17267506.
43. Gouilh, Meriadeg Ar; Puechmaille, Sébastien J.; Gonzalez, Jean-Paul; Teeling, Emma; Kittayapong, Pattamaporn; Manuguerra, Jean-Claude (October 2011). "SARS-Coronavirus ancestor's foot-prints in South-East Asian bat colonies and the refuge theory". *Infection, Genetics and Evolution*. 11 (7):

- 1690–1702. doi: 10.1016/j.meegid.2011.06.021. PMID 21763784.
44. Cui J, Han N, Streicker D, Li G, Tang X, Shi Z, et al. (October 2007). "Evolutionary relationships between bat coronaviruses and their hosts". *Emerging Infectious Diseases*. 13 (10): 1526–32. doi:10.3201/eid1310.070448. PMC 2851503. PMID 18258002.
45. Liu, S; Kang, J; Chen, J; Tai, D; Jiang, W; Hou, G; Chen, J; Li, J; Huang, B (2009). Field, Dawn (ed.). "Panorama phylogenetic diversity and distribution of type A influenza virus". *PLoS ONE*. 4 (3): 1–20. Bibcode:2009PLoSO...4.5022L. doi: 10.1371/journal.pone.0005022. PMC 2658884. PMID 19325912.
46. Scholtissek, C (1995). "Molecular evolution of influenza viruses" (PDF). *Virus Genes*. 11 (2–3): 209–215. doi:10.1007/BF01728660. PMID 8828147.
47. Peng, J; Yang, H; Jiang, H; Lin, YX; Lu, CD; Xu, YW; Zeng, J (2014). "The origin of novel avian influenza A (H7N9) and mutation dynamics for its human-to-human transmissible capacity". *PLoS ONE*. 9 (3): e93094. Bibcode:2014PLoSO...993094P. doi:10.1371/journal.pone.0093094. PMC 3966860. PMID 24671138.
48. Clancy, S (2008). "Genetics of the influenza virus". *Nature Education*. 1 (1).
49. "Plague of Athens: Another Medical Mystery Solved at University of Maryland". University of Maryland Medical Center. Archived from the original on 2015-12-04. Retrieved 2016-02-10.
50. Papagrigrakis, Manolis J.; Yapijakis, Christos; Synodinos, Philippos N.; Baziotopoulou-Valavani, Effie (2006). "DNA examination of ancient dental pulp incriminates typhoid fever as a probable cause of the Plague of Athens". *International Journal of Infectious Diseases*. 10 (3): 206–214. doi:10.1016/j.ijid.2005.09.001. PMID 16412683.
51. Olson, PE; Hames, CS; Benenson, AS; Genovese, EN (1996). "The Thucydides syndrome: Ebola déjà vu? (or Ebola reemergent?)". *Emerging Infect. Dis*. 2 (2): 155–156. doi:10.3201/eid0202.960220. PMC 2639821. PMID 8964060.
52. "Past pandemics that ravaged Europe" Archived 2017-10-07 at the Wayback Machine, BBC News, November 7, 2005
53. D. Ch. Stathakopoulos *Famine and Pestilence in the late Roman and early Byzantine Empire* (2007) 95
54. Rosen, William (2007), *Justinian's Flea: Plague, Empire, and the Birth of Europe* Archived 2017-07-24 at the Wayback Machine. Viking Adult; p. 3; ISBN 978-0-670-03855-8.
55. Andrew Ekonomou. *Byzantine Rome and the Greek Popes*. Lexington Books, 2007
56. Jump up to: a b Shahraki, Abdolrazag Hashemi (2016), *Plague in Iran: Its history and current status*.
57. Maddicott, J. R. (1 August 1997). "Plague in seventh century England". *Past & Present*. 156 (1): 7–54. doi:10.1093/past/156.1.7. ISSN 0031-2746.
58. Suzuki, A. (2011). "Smallpox and the epidemiological heritage of modern Japan: Towards a total history". *Medical History*. 55 (3): 313–18. doi:10.1017/S0025727300005329. PMC 3143877. PMID 21792253.
59. Kohn, George C. (2002). *Encyclopedia of Plague and Pestilence: From Ancient Times to the Present*. Princeton, New Jersey: Checkmark Books. p. 213. ISBN 978-0816048939.
60. Turner, David (November 1990). "The Politics of Despair: The Plague of 746–747 and Iconoclasm in the Byzantine Empire<sup>1</sup>". *Annual of the British School at Athens*. 85: 419–434. doi:10.1017/S006824540001577X. ISSN 2045-2403.
61. Austin Alchon, Suzanne (2003). *A pest in the land: new world epidemics in a global perspective*. University of New Mexico Press. p. 21. ISBN 978-0-8263-2871-7. Archived from the original on 2019-04-01. Retrieved 2016-04-22.
62. Heyman, Paul; Simons, Leopold; Cochez, Christel (7 January 2014). "Were the English Sweating Sickness and the Picardy Sweat Caused by Hantaviruses?". *Viruses*. 6 (1): 151–171. doi:10.3390/v6010151. PMC 3917436. PMID 24402305.
63. "American plague". *New Scientist*. December 19, 2000. Archived from the original on October 17, 2018. Retrieved October 17, 2018.
64. Acuna-Soto, R.; Romero, L. C.; Maguire, J. H. (2000). "Large epidemics of hemorrhagic fevers in Mexico 1545–1815". *The American Journal of Tropical Medicine and Hygiene*. 62 (6): 733–739. doi:10.4269/ajtmh.2000.62.733. PMID 11304065.
65. Acuna-Soto, Rodolfo; Stahle, D. W.; Cleaveland, M. K.; Therrell, M. D. (2002). "Megadrought and Megadeath in 16th Century Mexico". *Emerging Infectious Diseases*. 8 (4): 360–362. doi:10.3201/eid0804.010175. PMC 2730237. PMID 11971767.
66. Vågene, Åshild J.; Herbig, Alexander; Campana, Michael G.; Robles García, Nelly M.; Warinner, Christina; Sabin, Susanna; Spyrou, Maria A.; Andrades Valtueña, Aida; Huson, Daniel; Tuross, Noreen; Bos, Kirsten I.; Krause, Johannes (2018). "Salmonella enterica genomes from victims of a major sixteenth-century epidemic in Mexico". *Nature Ecology & Evolution*. 2 (3): 520–528. doi:10.1038/s41559-017-0446-6. PMID 29335577.
67. "American Indian Epidemics". Archived from the original on February 14, 2015.
68. "A History of Spain and Portugal". Archived from the original on 27 March 2017. Retrieved 16 November 2014.
69. Griffing, Sean M; Gamboa, Dionicia; Udhayakumar, Venkatachalam (30 August 2013). "The history of 20th century malaria control in Peru". *Malaria Journal*. 12: 303. doi:10.1186/1475-2875-12-303. PMC 3766208. PMID 24001096.

70. Bell, Walter George (1951). Belinda Hollyer (ed.). *The great Plague in London* (folio society ed.). Folio society by arrangement with Random House. Pages 3–5
71. Marr, John S.; Cathey, John T. (2010). "New Hypothesis for Cause of Epidemic among Native Americans, New England, 1616–1619". *Emerging Infectious Diseases*. 16 (2): 281–286. doi:10.3201/eid1602.090276. PMC 2957993. PMID 20113559.
72. Mann, Charles C. (December 2005). "Native intelligence". Archived from the original on 2018-11-23. Retrieved 2018-10-17.
73. Hays, J. N. (2005). *Epidemics and pandemics their impacts on human history*. Santa Barbara, Calif.: ABC-CLIO. p. 103. ISBN 978-1851096589.
74. Johansen, Bruce E. (2015). *American Indian Culture: From Counting Coup to Wampum* [2 volumes]: From Counting Coup to Wampum. ABC-CLIO. p. 88. ISBN 978-1-4408-2874-4. Retrieved 12 February 2020.
75. Newman, Kira L. S. (2012). "Shutt up: bubonic plague and quarantine in early modern England". *Journal of Social History*. 45 (3): 809–834. doi:10.1093/jsh/shr114. ISSN 0022-4529. PMID 22611587. Retrieved 12 February 2020.
76. Timothy Brook (1999). *The Confusions of Pleasure: Commerce and Culture in Ming China*. University of California Press. p. 163. ISBN 978-0-520-22154-3. Retrieved 31 March 2011.
77. Rogers, D.J.; Wilson, A.J.; Hay, S.I.; Graham, A.J. (2006). "The Global Distribution of Yellow Fever and Dengue". *Advances in Parasitology*. 62: 181–220. doi:10.1016/S0065-308X(05)62006-4. ISBN 9780120317622. ISSN 0065-308X. PMC 3164798. PMID 16647971.
78. Scasciamacchia, Silvia; Serrecchia, Luigina; Giangrossi, Luigi; Garofolo, Giuliano; Balestrucci, Antonio; Sammartino, Gilberto; Fasanella, Antonio (2012). "Plague Epidemic in the Kingdom of Naples, 1656–1658 - Volume 18, Number 1—January 2012 - Emerging Infectious Diseases journal - CDC". *Emerging Infectious Diseases*. 18 (1): 186–8. doi:10.3201/eid1801.110597. PMC 3310102. PMID 22260781.
79. Inc, Gideon Informatics; Berger, Dr Stephen (2019). *Measles: Global Status: 2019 edition*. GIDEON Informatics Inc. p. 514. ISBN 978-1-4988-2461-3. Retrieved 12 February 2020.
80. nl:Pestepidemie in Amsterdam
81. Ross, David. "UK travel and heritage – Britain Express UK travel guide". *The London Plague of 1665*. Archived from the original on 26 May 2019. Retrieved 14 July 2011.
82. Archives, The National. "Great Plague of 1665–1666 – The National Archives". Archived from the original on 28 April 2016. Retrieved 4 July 2016.
83. Jones, Colin (1996). "Plague and Its Metaphors in Early Modern France". *Representations* (53): 97–127. doi:10.2307/2928672. ISSN 0734-6018. JSTOR 2928672.
84. Casey, James (1999). *Early Modern Spain: A Social History*. Psychology Press. p. 37. ISBN 978-0-415-13813-0. Retrieved 12 February 2020.
85. Purvis, Thomas L. (2014). *Colonial America To 1763*. Infobase Publishing. p. 173. ISBN 978-1-4381-0799-8. Retrieved 12 February 2020.
86. Desjardins, Bertrand (1996). "Demographic Aspects of the 1702–1703 Smallpox Epidemic in the St. Lawrence Valley". *Canadian Studies in Population*. 23 (1): 49–67. doi:10.25336/P6459C.
87. Morens, David M. (2015). "The Past Is Never Dead—Measles Epidemic, Boston, Massachusetts, 1713 - Volume 21, Number 7—July 2015 - Emerging Infectious Diseases journal - CDC". *Emerging Infectious Diseases Journal*. 21 (7): 1257–60. doi:10.3201/eid2107.150397. PMC 4480406. PMID 26277799.
88. Mazan, Ryan; Gagnon, Alain; Desjardins, Bertrand (2009). "The Measles Epidemic of 1714–1715 in New France". *Canadian Studies in Population*. 36 (3–4): 295–323. doi:10.25336/P63P5Q.
89. Devaux, Christian A. (2013). "Small oversights that led to the Great Plague of Marseille (1720–1723): Lessons from the past". *Infection, Genetics and Evolution*. 14: 169–185. doi:10.1016/j.meegid.2012.11.016. PMID 23246639.
90. "Zabdiel Boylston and inoculation". Archived from the original on 5 September 2015. Retrieved 16 November 2014.
91. Cook, Noble David; Lovell, William George (2001). *Secret Judgments of God: Old World Disease in Colonial Spanish America*. University of Oklahoma Press. p. 127. ISBN 978-0-8061-3377-5. Retrieved 12 February 2020.
92. "Ambrosevideo.com". Archived from the original on 2016-04-17. Retrieved 2011-03-27.
93. Gagnon, Alain; Mazan, Ryan (2009). "Does exposure to infectious diseases in infancy affect old-age mortality? Evidence from a pre-industrial population". *Social Science & Medicine*. 68 (9): 1609–1616. doi:10.1016/j.socscimed.2009.02.008. PMID 19269727.
94. Krebsbach, Suzanne (1996). "The Great Charlestown Smallpox Epidemic of 1760". *The South Carolina Historical Magazine*. 97 (1): 30–37. ISSN 0038-3082. JSTOR 27570134.
95. Tognotti, Eugenia (February 2013). "Lessons from the History of Quarantine, from Plague to Influenza A". *Emerging Infectious Diseases*. 19 (2): 254–259. doi:10.3201/eid1902.120312. PMC 3559034. PMID 23343512.
96. LeMay, Michael C. (2016). *Global Pandemic Threats: A Reference Handbook: A Reference Handbook*. ABC-CLIO. p. 227. ISBN 978-1-4408-4283-2. Retrieved 12 February 2020.
97. Ranlet, Philip (2000). "The British, the Indians, and Smallpox: What Actually Happened at Fort Pitt in 1763?". *Pennsylvania History: A Journal of Mid-Atlantic Studies*. 67 (3): 427–441. ISSN 0031-4528. JSTOR 27774278.



98. Greg Lange, "Smallpox epidemic ravages Native Americans on the northwest coast of North America in the 1770s" Archived 2008-05-26 at the Wayback Machine, 23 Jan 2003, HistoryLink.org, Online Encyclopedia of Washington State History, accessed 2 Jun 2008
99. Prichard, Augustin; Fothergill, John (1894). "Influenza in 1775". *The Lancet*. 143 (3673): 175–176. doi:10.1016/S0140-6736(01)66026-4. Archived from the original on 2020-01-03. Retrieved 2019-07-05.
100. Rohé, George Henry; Robin, Albert (1908). *Text-book of Hygiene: A Comprehensive Treatise on the Principles and Practice of Preventive Medicine from an American Standpoint*. Davis. p. 428. Retrieved 12 February 2020. *Spain 1788 dengue fever*.
101. Houston, C. S.; Houston, S. (2000). "The first smallpox epidemic on the Canadian Plains: In the fur-traders' words". *The Canadian Journal of Infectious Diseases*. 11 (2): 112–5. doi:10.1155/2000/782978. PMC 2094753. PMID 18159275.
102. Waldman, Carl; Braun, Molly (2009). *Atlas of the North American Indian*. Infobase Publishing. p. 295. ISBN 978-1-4381-2671-5. Retrieved 12 February 2020.
103. [The History of Small-Pox in Australia, 1788–1908, JHL Cumpston, (1914, Government Printer, Melb.) This epidemic is unlikely to have been a natural event. see, Warren (2013) doi:10.1080/14443058.2013.849750 After Cook and coinciding with Colonisation "With the arrival of the Europeans, the Gadigal population was virtually wiped. In 1789 and 1790 a smallpox epidemic swept through the Aboriginal population around Sydney" Archived 2008-06-25 at the Wayback Machine
104. "Epidemics". Archived from the original on 2013-07-22. Retrieved 2008-06-08.
105. "Tiger mosquitoes and the history of yellow fever and dengue in Spain". Archived from the original on 4 August 2017. Retrieved 16 November 2014.
106. Andrew Davidson (1893). *Hygiene & diseases of warm climates*. Pentland. p. 337. Retrieved 31 March 2011.
107. "Odessa, 1812: Plague and Tyranny at the Edge of the Empire". *Balkanist*. 5 December 2015. Retrieved 13 February 2020.
108. J. N. Hays (2005). *Epidemics and pandemics: their impacts on human history*. ABC-CLIO. ISBN 978-1-85109-658-9. Retrieved 29 March 2011.[page needed]
109. Chisholm, Hugh, ed. (1911). "Yellow Fever" . *Encyclopædia Britannica*. 28 (11th ed.). Cambridge University Press. pp. 910–911.
110. "Aboriginal Health History". Archived from the original on 27 September 2011. Retrieved 16 November 2014.
111. Barry Leadbeater. "South Australian History Timeline (19th Century)". Archived from the original on 28 November 2014. Retrieved 16 November 2014.
112. A History of the Human Plague in Iran Archived 2011-07-19 at the Wayback Machine, Mohammad Azizi, Farzaneh Azizi
113. Kuhnke, Laverne. *Lives at Risk: Public Health in Nineteenth-Century Egypt*. ark.cdlib.org Archived 2008-11-20 at the Wayback Machine, Berkeley: University of California Press, c1990.
114. Gallagher, Nancy. *Egypt's Other Wars: Epidemics and the Politics of Public Health*. Syracuse University Press, c1990. Published by the American University in Cairo Press. ISBN 977-424-295-5[page needed]
115. Wilford, John Noble (15 April 2008). "How Epidemics Helped Shape the Modern Metropolis". *The New York Times*. Retrieved 13 February 2020.
116. "Smallpox decimates tribes; survivors join together – Timeline – Native Voices". www.nlm.nih.gov. Archived from the original on 16 August 2016. Retrieved 4 July 2016.
117. Gallagher, The Reverend John A. (1936). "The Irish Emigration of 1847 and Its Canadian Consequences". *Canadian Catholic Historical Association Report, University of Manitoba Web Site*. Archived from the original on 2007-10-11. Retrieved 2008-03-23.
118. a s, &NA (1849). "On the Influenza, or Epidemic Catarrhal Fever of 1847–8". *The American Journal of the Medical Sciences*. 18 (35): 148–154. doi:10.1097/00000441-184907000-00018. PMC 5277660.
119. Daly, Walter J. (2008). "The Black Cholera Comes to the Central Valley of America in the 19th Century - 1832, 1849, and Later". *Transactions of the American Clinical and Climatological Association*. 119: 143–153. ISSN 0065-7778. PMC 2394684. PMID 18596846.
120. Practitioner. 1877. Retrieved 29 March 2011.
121. Archived 2015-01-03 at the Wayback Machine About Cholera epidemic of Copenhagen 1853
122. John Snow (1855). *On the mode of communication of cholera*. John Churchill. Retrieved 29 March 2011.
123. Pryor, E. G. (1975). "The great plague of Hong kong". *Journal of the Hong Kong Branch of the Royal Asiatic Society*. 15: 61–70. JSTOR 23881624. PMID 11614750.
124. "Australian Medical Pioneers Index (AMPI) – Colonial Medical Life". Archived from the original on 29 June 2017. Retrieved 16 November 2014.
125. Beveridge, W.I.B. *Influenza, the Last Great Plague* (Heinemann, London, 1977)[page needed]
126. Swanky, Tom (2016). *The Smallpox War in Nuxalk Territory*. British Columbia, Canada: Dragon Heart. p. 93. ISBN 978-1365410161.
127. "1902Encyclopedia.com". Archived from the original on 4 March 2016. Retrieved 16 November 2014.
128. Cited in: Howlin, Diego (2004). "Vómito Negro, Historia de la fiebre amarilla, en Buenos Aires de

- 1871" Archived 2017-06-07 at the Wayback Machine, Revista Persona.
129. "Death of Forty Thousand Fijians from Measles". *Liverpool Mercury*. 29 Sep 1875. Retrieved 9 Nov 2012.
130. Chisholm, Hugh, ed. (1911). "Plague" . *Encyclopædia Britannica*. 21 (11th ed.). Cambridge University Press. pp. 693–705.
131. Great Britain. Local Government Board (1893). *Further report and papers on epidemic influenza, 1889–92: with an introduction by the medical officer of the Local Government Board*. Eyre. Retrieved 29 March 2011.[page needed]
132. African trypanosomiasis Archived 2016-12-04 at the Wayback Machine, WHO
133. Echenberg, Myron (2007). *Plague Ports: The Global Urban Impact of Bubonic Plague: 1894–1901*. Sacramento: New York University Press. p. 231. ISBN 978-0-8147-2232-9.
134. "Reanalyzing the 1900–1920 sleeping sickness epidemic in Uganda". Archived from the original on 2009-09-16. Retrieved 2008-01-07.
135. "Texas Department of State Health Services, History of Plague". Archived from the original on 2013-06-26. Retrieved 2008-07-01.
136. Blackburne, George Hugh Spencer; Anderson, T. L. (1903). Report on the outbreak of plague at Fremantle – via Wikisource.
137. "In Memory of the 1910 Harbin Plague". Archived from the original on 2017-10-28. Retrieved 2011-01-14.
138. Foster, Harold D.; Hoffer, Abram (1 January 2007). "Chapter 16 - Hyperoxidation of the Two Catecholamines, Dopamine and Adrenaline: Implications for the Etiologies and Treatment of Encephalitis Lethargica, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Schizophrenia". *Oxidative Stress and Neurodegenerative Disorders*. Elsevier Science B.V.: 369–382. doi:10.1016/B978-044452809-4/50157-5. Retrieved 11 February 2020.
139. Patterson, K. D.; Pyle, G. F. (1991). "The geography and mortality of the 1918 influenza pandemic". *Bulletin of the History of Medicine*. 65 (1): 4–21. PMID 2021692.
140. Ravenel, Mazÿk P. (May 1938). "The Croydon Epidemic of Typhoid Fever". *American Journal of Public Health and the Nations Health*. 28 (5): 644–646. doi:10.2105/AJPH.28.5.644. PMC 1529192. PMID 18014847.
141. William E. Paul (1 May 2008). *Fundamental immunology*. Lippincott Williams & Wilkins. ISBN 978-0-7817-6519-0. Archived from the original on 2 July 2014. Retrieved 29 March 2011.
142. Spross, Åke (21 January 2018). "Så kan vaccin utrota sjukdomar" (in Swedish). *Uppsala Nya Tidning*. Archived from the original on 21 January 2018. Retrieved 12 March 2019.
143. "Sjukdomsinformation om smittkoppor" (in Swedish). Public Health Agency of Sweden. 17 October 2013. Archived from the original on 2 February 2017. Retrieved 12 March 2019.
144. *Geschiedenis 24 – Polio in Staphorst* Archived 2013-07-14 at the Wayback Machine. *Geschiedenis24.nl* (2010-11-17). Retrieved on 2014-05-12.
145. "New, Deadly Flu Strain Detected in Albany Co". *Schenectady Gazette*. Associated Press. January 24, 1975. p. 3. Retrieved August 3, 2012.
146. "The control and eradication of smallpox in South Asia". [www.smallpoxhistory.ucl.ac.uk](http://www.smallpoxhistory.ucl.ac.uk). Archived from the original on 2008-10-19. Retrieved 2008-12-18.
147. UNAIDS (2010) report on the global AIDS epidemic'[permanent dead link]
148. Dutt, Ashok (2006). "Surat Plaque of 1994 re-examined" (PDF). *Southeast Asian Journal of Tropical Medicine and Public Health*. 37 (4): 755–60. PMID 17121302. Archived (PDF) from the original on 6 February 2016. Retrieved 19 June 2016.
149. Lai-Meng Looi; Kaw-Bing Chua (2007). "Lessons from the Nipah virus outbreak in Malaysia" (PDF). *The Malaysian Journal of Pathology*. Department of Pathology, University of Malaya and National Public Health Laboratory of the Ministry of Health, Malaysia. 29 (2): 63–67. Archived (PDF) from the original on 30 August 2019.
150. "Dengue in the Americas: The Epidemics of 2000". Archived from the original on 2017-10-17. Retrieved 2008-08-05.
151. "Nigeria cholera outbreak kills 400". 2001-11-26. Archived from the original on 19 December 2003. Retrieved 16 November 2014.
152. "Cholera Spreads Through South Africa Townships". Archived from the original on 3 June 2009. Retrieved 16 November 2014.
153. *Epidemiologic Clues to SARS Origin in China June 2004*, [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov), accessed 16 February 2020
154. "How Hong Kong Beat SARS: Lessons Learned".
155. Hsieh, Y. H.; King, C. C.; Chen, C. W.; Ho, M. S.; Lee, J. Y.; Liu, F. C.; Wu, Y. C.; Jiunn-Shyan, Julianwu (2005). "Quarantine for SARS, Taiwan". *Emerging Infectious Diseases*. 11 (2): 278–282. doi:10.3201/eid1102.040190. PMC 3320446. PMID 15752447.
156. "Post SARS: Key milestones". 2018-01-04.
157. "Severe Acute Respiratory Syndrome (SARS)".
158. Bertherat, Eric; Bekhoucha, Souad; Chougrani, Saada; Razik, Fathia; Duchemin, Jean B.; Houti, Leila; Deharib, Larbi; Fayolle, Corinne; Makrrougrass, Banaouda; Dali-Yahia, Radia; Bellal, Ramdan; Belhabri, Leila; Chaieb, Amina; Tikhomirov, Evgueni; Carniel, Elisabeth (2007). "Plague Reappearance in Algeria after 50 Years, 2003". *Emerging Infectious Diseases*. 13 (10): 1459–1462. doi:10.3201/eid1310.070284. PMC 2851531. PMID 18257987.
159. "World Health Organization action in Afghanistan aims to control debilitating leishmaniasis". Archived from the original on 12 October 2017. Retrieved 16 November 2014.
- 160.

161. Faruque, S. M.; Islam, M. J.; Ahmad, Q. S.; Faruque, A. S. G.; Sack, D. A.; Nair, G. B.; Mekalanos, J. J. (2005). "Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage". *Proceedings of the National Academy of Sciences*. 102 (17): 6119–6124. Bibcode:2005PNAS..102.6119F. doi:10.1073/pnas.0502069102. PMC 1087956. PMID 15829587.
162. Dengue fever in Indonesia - update 4 11 May 2004 www.who.int, accessed 16 February 2020
163. Staff Reporter. "Cholera epidemic takes hold in Senegal". *The M&G Online*. Archived from the original on 3 February 2017. Retrieved 16 November 2014.
164. "Ebola virus disease" (Press release). World Health Organization (WHO). 12 February 2018. Retrieved 26 February 2020.
165. "Mali: Yellow fever epidemic in Kayes". 2005-11-11. Archived from the original on 2009-01-12. Retrieved 2008-11-24.
166. Koh, B. K.; Ng, L. C.; Kita, Y.; Tang, C. S.; Ang, L. W.; Wong, K. Y.; James, L.; Goh, K. T. (2008). "The 2005 dengue epidemic in Singapore: Epidemiology, prevention and control" (PDF). *Annals of the Academy of Medicine, Singapore*. 37 (7): 538–45. PMID 18695764. Archived (PDF) from the original on 2017-07-06. Retrieved 2018-10-17.
167. Worst cholera outbreak in Angola Archived 2017-04-29 at the Wayback Machine, BBC
168. Plague in the Democratic Republic of the Congo 14 June 2006 www.who.int, accessed 26 February 2020
169. Plague in the Democratic Republic of the Congo 13 October 2006 www.who.int, accessed 26 February 2020
170. "Malaria Epidemic Sweeps Northeast India". Archived from the original on 2017-02-03. Retrieved 2008-07-01.
171. "Dengue epidemic threatens India's capital". *News-Medical.net*. 2 October 2006. Archived from the original on 15 January 2009. Retrieved 16 November 2014.
172. "WHO – Chikungunya in India". Archived from the original on 23 December 2013. Retrieved 16 November 2014.
173. Khan, E.; Siddiqui, J.; Shakoor, S.; Mehraj, V.; Jamil, B.; Hasan, R. (2007). "Dengue outbreak in Karachi, Pakistan, 2006: Experience at a tertiary care center". *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 101 (11): 1114–1119. doi:10.1016/j.trstmh.2007.06.016. PMID 17706259.
174. Epidemiology of Dengue Disease in the Philippines (2000–2011): A Systematic Literature Review November 2014 PLoS Neglected Tropical Diseases via www.researchgate.net, accessed 16 February 2020
175. "Mourners die as fever grips Congo." Archived 2012-07-30 at WebCite Sydney Morning Herald, August 30, 2007
176. Xan Rice (2007-02-22). "Fatal outbreak not a cholera epidemic, insists Ethiopia". *The Guardian*. Archived from the original on 26 October 2017. Retrieved 16 November 2014.
177. Cholera death toll in India rises Archived 2017-11-11 at the Wayback Machine, BBC News
178. Cholera outbreak in Iraq growing Archived 2017-02-04 at the Wayback Machine, Associated Press
179. Vaccine-linked polio hits Nigeria Archived 2016-08-20 at the Wayback Machine, BBC News
180. Dengue fever epidemic hits Caribbean, Latin America Archived 2009-08-03 at the Wayback Machine, Reuters
181. "Somalia cholera death fears grow". 2007-04-28. Archived from the original on 5 October 2017. Retrieved 16 November 2014.
182. Cholera epidemic losing its sting Archived 2008-06-26 at the Wayback Machine
183. Thousands hit by Brazil outbreak of dengue edition.cnn.com, accessed 16 February 2020
184. Cambodia suffers worst dengue epidemic, 407 dead Archived 2009-11-11 at the Wayback Machine, Reuters
185. "Cholera epidemic in western Chad kills 123". 2004-09-02. Archived from the original on 2009-01-12. Retrieved 2008-06-08.
186. Epidemiology of Recurrent Hand, Foot and Mouth Disease, China, 2008–2015 wwwnc.cdc.gov Emerging Infectious Diseases, Volume 24, Number 3—March 2018, Accessed 23 February 2020
187. "Madagascar: eighteen dead from Bubonic Plague, five in hospital since 1 January 2008". Archived from the original on May 9, 2009.
188. "Dengue cases in Philippines rise by 43 percent: government". Archived from the original on 17 October 2017. Retrieved 16 November 2014.
189. Vietnam PM urges action against diarrhea outbreak Archived 2008-04-16 at the Wayback Machine, Thanh Nien Daily
190. "Cholera Country Profile: Zimbabwe" (PDF). World Health Organization - Global Task Force on Cholera Control. 31 October 2009. Retrieved 16 February 2020.
191. The History of Dengue Outbreaks in the Americas www.ncbi.nlm.nih.gov, accessed 16 February 2020
192. "NDTV Report". Archived from the original on 2009-02-25. Retrieved 2009-02-23.
193. McCredie, J. (2009). "Dengue fever epidemic hits northern Australia". *BMJ*. 338: b967. doi:10.1136/bmj.b967. PMID 19273518.
194. Odigwe, C. (2009). "West Africa has worst meningitis epidemic for 10 years". *BMJ*. 338: b1638. doi:10.1136/bmj.b1638. PMID 19383759.
195. "First Global Estimates of 2009 H1N1 Pandemic Mortality Released by CDC-Led Collaboration". *Centers for Disease Control and Prevention*. 2012-06-25. Archived from the original on 2012-07-01. Retrieved 2017-09-09.
196. "2009 Swine-Flu Death Toll 10 Times Higher Than Thought". *LiveScience.com*. Archived from the original on 7 November 2014. Retrieved 16 November 2014.

197. Ministère de la Santé Publique et de la Population official cholera report 22 March 2011, [www.mspp.gov.ht](http://www.mspp.gov.ht) Archived 2016-12-28 at the Wayback Machine[full citation needed].
198. "Why Cholera Persists in Haiti Despite an Abundance of Aid". [www.npr.org](http://www.npr.org). Archived from the original on 2015-04-28. Retrieved 2018-04-05.
199. "Doctorswithoutborders.org". MSF USA. Archived from the original on 27 September 2011. Retrieved 16 November 2014.
200. Democratic Republic of Congo: More measles vaccinations needed". Médecins Sans Frontières (MSF) International. Archived from the original on 2 November 2014. Retrieved 16 November 2014.
201. Vietnam on alert as common virus kills 81 children - Yahoo News Archived 2016-03-05 at the Wayback Machine. [News.yahoo.com](http://News.yahoo.com) (2011-08-19). Retrieved on 2014-05-12.
202. Nguyen, Ngoc TB; Pham, Hau V.; Hoang, Cuong Q.; Nguyen, Tien M.; Nguyen, Long T.; Phan, Hung C.; Phan, Lan T.; Vu, Long N.; Tran Minh, Nguyen N. (2014). "Epidemiological and clinical characteristics of children who died from hand, foot and mouth disease in Vietnam, 2011". *BMC Infectious Diseases*. 14: 341. doi:10.1186/1471-2334-14-341. PMC 4068316. PMID 24942066.
203. Surveillance, forecasting and response International conference on dengue control, 27-29 February 2012 [www.emro.who.int](http://www.emro.who.int) accessed 16 February 2020
204. Yuill, Thomas M.; Woodall, John P.; Baekeland, Susan (2013). "Latest outbreak news from ProMED-mail. Yellow fever outbreak—Darfur Sudan and Chad". *International Journal of Infectious Diseases*. 17 (7): e476-e478. doi:10.1016/j.ijid.2013.03.009.
205. Donnelly, Christl A.; Malik, Mamun R.; Elkholy, Amgad; Cauchemez, Simon; Kerkhove, Maria D. Van (2019). "Worldwide Reduction in MERS Cases and Deaths since 2016 - Volume 25, Number 9—September 2019 - Emerging Infectious Diseases journal - CDC". *Emerging Infectious Diseases*. 25 (9): 1758-1760. doi:10.3201/eid2509.190143. PMC 6711233. PMID 31264567.
206. "Middle East Respiratory Syndrome coronavirus (MERS-CoV) - Saudi Arabia. World Health Organisation (2015-06-11). Retrieved on 2015-06-20". Archived from the original on 2015-06-16. Retrieved 2015-06-20.
207. "Middle East respiratory syndrome coronavirus (MERS-CoV) - United Arab Emirates". World Health Organization. 31 January 2020.
208. "Vietnam measles outbreak kills more than 100 people, mostly children". *Sydney Morning Herald*. 18 April 2014.
209. "2014-2016 Ebola Outbreak in West Africa (section titled 'Impact')". [www.cdc.gov](http://www.cdc.gov). 2019-08-22. Retrieved 2020-02-14.
210. "Situation summary Latest available situation summary, 26 June 2015. World Health Organization (2015-06-19). Retrieved on 2015-06-20". Archived from the original on 5 June 2016. Retrieved 27 June 2015.
211. Gignoux, Etienne; Idowu, Rachel; Bawo, Luke; Hurum, Lindis; Sprecher, Armand; Bastard, Mathieu; Porten, Klaudia (2015). "Use of Capture-Recapture to Estimate Underreporting of Ebola Virus Disease, Montserrado County, Liberia". *Emerging Infectious Diseases*. 21 (12): 2265-2267. doi:10.3201/eid2112.150756. PMC 4672419. PMID 26583831.
212. "Número de casos informados de artritis epidémica chikungunya en las Américas - SE 5 (February 6, 2015)". Pan American Health Organization. Archived from the original on February 18, 2015. Retrieved February 11, 2015.
213. "Plague - Madagascar". WHO. World Health Organization. Archived from the original on 2 May 2019. Retrieved 5 July 2016.
214. "Odisha grapples with jaundice outbreak". *Deccan Herald*. 17 February 2015. Archived from the original on 17 February 2015. Retrieved 17 February 2015.
215. Press Trust of India (March 21, 2015). "Swine flu deaths at 1895; number of cases near 32K mark". *The Indian Express*. Archived from the original on October 12, 2015. Retrieved March 21, 2015.
216. "India struggles with deadly swine flu outbreak". *BBC News*. 20 February 2015. Archived from the original on 21 February 2015. Retrieved 21 February 2015.
217. "Death toll Gujarat". *Business Standard*. 15 March 2015. Archived from the original on 2 April 2015. Retrieved 15 March 2015.
218. "WHO | Zika: the origin and spread of a mosquito-borne virus". WHO. Retrieved 19 February 2020.
219. "Yellow fever - countries with dengue: alert 2016-03-28 20:39:56 Archive Number: Archive Number: 20160328.4123983". ProMED-mail. International Society for Infectious Diseases. Archived from the original on 10 April 2016. Retrieved 29 March 2016.
220. WHO Regional Office for the Eastern Mediterranean Cholera Situation in Yemen November 2019". Retrieved 30 November 2019.
221. Encephalitis outbreak: AES is a perennial issue in eastern Uttar Pradesh, northern Bihar Bihar's AES data summary looks more like a repeat of 2017 when a major JEV outbreak in Uttar Pradesh's Gorakhpur claimed the lives of many children. 17 June 2019 [www.indiatvnews.com](http://www.indiatvnews.com), accessed 17 February 2020
222. "Nipah virus contained, last two positive cases have recovered: Kerala Health Min". *The News Minute*. 2018-06-11. Retrieved 2020-02-16.
223. "Operations Dashboard for ArcGIS". [who.maps.arcgis.com](http://who.maps.arcgis.com). Archived from the original on 21 August 2019. Retrieved 20 February 2020.
224. "Ebola Virus Disease Outbreak Uganda Situation Reports". WHO | Regional Office for Africa. Archived from the original on 20 June 2019. Retrieved 3 September 2019.

225. "DR Congo measles: More than 6,000 dead in world's worst outbreak". BBC News. 2020-01-08. Retrieved 2020-02-28.
226. "Two more deaths from measles in samoa over new year period". Radio New Zealand. 2020-01-07. Archived from the original on 2020-01-07.
227. ^ "Tracking coronavirus: Map, data and timeline". Bnonews. bnonews.com. 2 February 2020. Retrieved 16 February 2020.
228. ^ "Is Coronavirus an Epidemic That Has No Permanent Cure Except Lopinavir And Ritonavir". www.medixocentre.com. 11 February 2020. Retrieved 11 February 2020.
229. McKie, Robin (10 December 2017). "Scientists trace 2002 Sars virus to colony of cave-dwelling bats in China". *The Guardian*. ISSN 0029-7712. Retrieved 10 December 2017.
230. Corman VM, Muth D, Niemeyer D, Drosten C (2018). "Hosts and Sources of Endemic Human Coronaviruses". *Advances in Virus Research*. 100: 163–88.
231. Worobey M, Holmes EC. Evolutionary aspects of recombination in RNA viruses. *Journal of General Virology*. 1999;80 (Pt 10) (10):2535–43. doi:10.1099/0022-1317-80-10-2535. PMID 10573145.
232. Lukashev AN. Role of recombination in evolution of enteroviruses. *Reviews in Medical Virology*. 2005;15(3):157–67. doi:10.1002/rmv.457. PMID 15578739.
233. Umene K. Mechanism and application of genetic recombination in herpesviruses. *Reviews in Medical Virology*. 1999;9(3):171–82. doi:10.1002/(SICI)1099-1654(199907/09)9:3<171: AID-RMV243>3.0.CO;2-A. PMID 10479778.
234. Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RA, Eichelberger MC. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108(51):20748–53. doi:10.1073/pnas.1113801108. PMID 22143798. Bibcode: 2011PNAS.10820748S.
235. Moss RB, Davey RT, Steigbigel RT, Fang F. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. *The Journal of Antimicrobial Chemotherapy*. 2010;65(6):1086–93. doi:10.1093/jac/dkq100. PMID 20375034.
236. Barr JN, Fearn R (June 2010). "How RNA viruses maintain their genome integrity". *The Journal of General Virology*. 91 (Pt 6): 1373–87. doi:10.1099/vir.0.020818-0. PMID 20335491.
237. Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, et al. (June 2016). "Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses". *Trends in Microbiology*. 24 (6): 490–502. doi: 10.1016/j.tim.2016.03.003. PMID 27012512.
238. Wu, F., Zhao, S., Yu, B. et al. A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265–269 (2020). <https://doi.org/10.1038/s41586-020-2008-3>.
239. Galton, Sir Francis (1894). *Natural Inheritance*. Macmillan. ISBN 978-1297895982
240. "The Galton Board". www.galtonboard.com. Four Pines Publishing, Inc. Retrieved 2018-03-06.
241. Nicola Davison (6 October 2017). "Why can't we cure the common cold?", *The Guardian*
242. Jacobs SE, Lamson DM, St George K, Walsh TJ (January 2013). "Human rhinoviruses". *Clinical Microbiology Reviews*. 26 (1): 135–62. doi:10.1128/CMR.00077-12. PMC 3553670. PMID 23297263
243. Robert B Couch (2005). "Rhinoviruses:Replication". In Anne O'Daly (ed.). *Encyclopedia of Life Sciences*. John Wiley. ISBN 978-0-470-01590-2.
244. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, et al. (1985). "Structure of a human common cold virus and functional relationship to other picornaviruses". *Nature*. 317 (6033): 145–53. Bibcode:1985Natur. 317..145R. doi:10.1038/317145a0. PMID 2993920.
245. Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, et al. (September 1986). "The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating". *Science*. 233 (4770): 1286–93. Bibcode:1986Sci...233.1286S. doi:10.1126/science.3018924. PMID 3018924.
246. Farr BM, Gwaltney JM, Adams KF, Hayden FG (July 1984). "Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds". *Antimicrobial Agents and Chemotherapy*. 26 (1): 31–4. doi:10.1128/aac.26.1.31. PMC 179911. PMID 6089652.
247. Mousnier A, Bell AS, Swieboda DP, Morales-Sanfrutos J, Pérez-Dorado I, Brannigan JA, et al. (June 2018). "Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus". *Nature Chemistry*. 10 (6): 599–606. Bibcode:2018NatCh. 10..599M. doi:10.1038/s41557-018-0039-2. PMC 6015761. PMID 29760414.
248. Mary Engel (February 13, 2009). "Rhinovirus strains' genomes decoded; cold cure-all is unlikely: The strains are probably too different for a single treatment or vaccine to apply to all varieties, scientists say". *Los Angeles Times*.
249. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ (July 2009). "Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization". *Journal of Virology*. 83 (14): 7040–8. doi:10.1128/JVI.00557-09. PMC 2704786. PMID 19403680.
250. Carroll, Lewis (1991) [1871]. "2: The Garden of Live Flowers". *Through the Looking-Glass (The Millennium Fulcrum Edition 1.7 ed.)*. Project Gutenberg. Retrieved 26 September 2017.
251. Van Valen, Leigh (1973). "A new evolutionary law" (PDF). *Evolutionary Theory*. 1: 1–30.

252. Bell, G. (1982). The Masterpiece of Nature: The Evolution and Genetics of Sexuality. University of California Press, Berkeley, 378 pp.
253. Magain, N; Sérusiaux, E (2014). "Do photobiont switch and cephalodia emancipation act as evolutionary drivers in the lichen symbiosis? A case study in the Pannariaceae (Peltigerales)". PLoS ONE. 9 (2): e89876. Bibcode:2014PLoSO...989876M. doi: 10.1371/journal.pone.0089876. PMC 3933699. PMID 24587091.